{"id":562,"date":"2023-08-14T19:32:05","date_gmt":"2023-08-14T19:32:05","guid":{"rendered":"https:\/\/www.msapr.com\/main\/?page_id=562"},"modified":"2026-04-30T16:52:39","modified_gmt":"2026-04-30T16:52:39","slug":"interview-archives-before-2025","status":"publish","type":"page","link":"https:\/\/www.msapr.com\/main\/interview-archives-before-2025\/","title":{"rendered":"Achieve Interviews before 2025"},"content":{"rendered":"

Archieve interview before 2025<\/h2>\n

Recent interviews<\/a><\/strong><\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n\n\n

<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 1028: January 17, 2025<\/h4>\n

\"1028\"B. Frank Gupton, Ph.D.,<\/strong> Chief Executive Officer, Medicines for All Institute at Virginia Commonwealth University, on eliminating waste and inefficiency in the drug manufacturing process.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1025: December 20, 2024<\/h4>\n

\"1025\"Kelly Cobey, Ph.D.,<\/strong> Scientist at the University of Ottawa Heart Institute, on the problems surrounding reproducibility in the field of biomedical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 1024: December 13, 2024<\/h4>\n

\"1024\"Jay Short, Ph.D.,<\/strong> Chairman, CEO, and Co-founder of BioAtla, on selectively targeting tumor cells to treat patient populations with high unmet need.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1023: December 6, 2024<\/h4>\n

\"1023\"David J. Earp, J.D., Ph.D.,<\/strong> President and CEO of Circle Pharma, on developing a new generation of macrocycle therapies to treat historically undruggable targets.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 1022: November 22, 2024<\/h4>\n

\"1022\"Nikole Kimes, Ph.D.,<\/strong> Co-Founder and Chief Executive Officer of Siolta Therapeutics, on pioneering a preventative approach to diseases stemming from the gut microbiome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1018: October 25, 2024<\/h4>\n

\"1018\"Chris Gibson, Ph.D.,<\/strong> Co-Founder and CEO of Recursion, on leveraging machine learning and AI-enabled maps of biology to further advance drug discovery and development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 1015: October 4, 2024<\/h4>\n

\"1015\"Marcio Souza,<\/strong> President and CEO of Praxis Precision Medicines, on creating a novel treatment to address an unmet medical need in patients with DEE.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1011: September 6, 2024<\/h4>\n

\"1011\"Kenneth Getz,<\/strong> Executive Director and Research Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine, on bringing together industry insights through a pre-competitive DCT consortium.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 1010: August 30, 2024<\/h4>\n

\"1010\"Louis Reese,<\/strong> Co-founder and Executive Chairman of Vaxxinity, on leveraging an innovative platform to deliver immunotherapeutic vaccines for chronic diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1009: August 23, 2024<\/h4>\n

\"1009\"Dr. Catherine Pearce,<\/strong> CEO and Co-founder of JucaBio, on bringing innovative new drugs with flexible, small organizational units.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 1008: August 16, 2024<\/h4>\n

\"1008\"Brian Feldman, M.D., Ph.D.,<\/strong> Walter L. Miller Distinguished Professor at the University of California, San Francisco, Department of Pediatrics, Devision of Pediatric Endocrinology, on finding the mechanism for converting white adipocytes to beige adipocytes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1006: August 2, 2024<\/h4>\n

\"1006\"Pablo Penaloza-MacMaster, Ph.D.,<\/strong> Associate Professor of Microbiology-Immunology, Northwestern University, on discovering the antitumoral effects of r3LCMV.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 1005: July 26, 2024<\/h4>\n

\"1005\"Benjamin Ineichen, M.D., Ph.D., <\/strong> Junior Group Leader at the Center for Reproducible Science at the University of Zurich, on how to improve the translational success rate of therapeutical development from animal to human studies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1002: June 28, 2024<\/h4>\n

\"1002\"David Gutmann, M.D., Ph.D., <\/strong> Professor at Washington University of Medicine in St. Louis, on the groundbreaking discovery of a novel treatment for preventing the formation of tumors stemming from NF1.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 1000: June 14, 2024<\/h4>\n

\"1000\"Ken Horne, <\/strong> Managing Partner at AN Venture Partners, on investing in Japan bioscience, but going global from day one.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 998: May 31, 2024<\/h4>\n

\"998\"Eli Wallace, Ph.D.,<\/strong> CEO of BridgeBio Oncology Therapeutics, on paving the way in next-generation oncological therapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 996: May 17, 2024<\/h4>\n

\"996\"Seema Nandi, Ph.D., <\/strong> Co-Founder and CEO at SelSym Biotech, on developing innovative synthetic platelets to address clinical needs in bleeding management and improve patient outcomes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 993: April 26, 2024<\/h4>\n

\"993\"Justin Ichida, Ph.D.,<\/strong> Associate Professor in the Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, on making a novel discovery that could pave the way for future TBI treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 991: April 5, 2024<\/h4>\n

\"991\"Harsha K. Rajasimha, M.S., Ph.D., <\/strong> Founder and CEO of Jeeva Clinical Trials, on bringing clinical trials into the modern era and leveraging an all-in-one platform to make clinical trials more efficient and accessible.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 990: March 28, 2024<\/h4>\n

\"990-1\"\"990-2\" Mark Kreston and Calman Prussin, M.D.,<\/strong> Chief Commercial Officer and Chief Scientific Officer of Areteia Therapeutics, on developing an innovative therapy to better the lives of asthma patients.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 987: March 8, 2024<\/h4>\n

\"987\"Jonathan Kipnis, Ph.D.,<\/strong> Edith L. Wolff Distinguished Professor of Neurology, Neuroscience and Neurosurgery, and Director of the Brain Immunology and Glia Center at the Washington University School of Medicine in St. Louis, on making the groundbreaking discovery of a direct connection between the brain and dura matter.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 985: February 23, 2024<\/h4>\n

\"985\"Stephen Badylak, Ph.D., M.D.,<\/strong> Co-Founder, Chief Science Officer, ECM Therapeutics, on utilizing novel versions of ECM to address unmet medical needs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 984: February 16, 2024 <\/h4>\n

\"984\"Matt Kane,<\/strong> CEO and Director at Tune Therapeutics, on pioneering the next generation of epigenome editing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 982: February 2, 2024<\/h4>\n

\"982\"Roger Hajjar, M.D.,<\/strong> Director of MGB Gene and Cell Therapy Institute at Mass General Brigham, on streamlining the discovery and trials of innovative treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 981: January 26, 2024 <\/h4>\n

\"981\"Dr. Michael Crackower, Ph.D,<\/strong> Founder and Chief Scientific Officer at BrainChild Bio, Inc., on revolutionizing CAR T-cell therapy in CNS cancers.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 980: January 19, 2024<\/h4>\n

\"980\"Dr. Michael Jensen, M.D.,<\/strong> Research Professor in the Center for Genetic Epidemiology, Department of Population and Public Health Sciences at Keck School of Medicine, University of Southern California, on her groundbreaking research on hyperemesis gravidarum and discovering the cause of the disease and identifying potential treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 976: December 22, 2023 <\/h4>\n

\"976\"Dr. Michael Crackower, Ph.D,<\/strong> Chief Scientific Officer at Ventus Therapeutics, on leveraging structural biology and computational chemistry tools to pioneer novel medicines.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 972: November 17, 2023<\/h4>\n

\"972\"Andrew Allen, M.D., Ph.D.,<\/strong> Co-founder, President and CEO of Gritstone bio, on leading the way in developing next-generation vaccines.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 968: October 13, 2023 <\/h4>\n

\"968\"Peter M. Tessier, Ph.D.,<\/strong> Albert M. Mattocks Professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, on paving the way for the use of machine learning to optimize therapeutic antibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 963: September 8, 2023<\/h4>\n

\"963\"Hamideh Parhiz, Pharm.D., Ph.D.,<\/strong> Research Assistant Professor in the Division of Infectious Diseases at the Perelman School of Medicine at the University of Pennsylvania, on pioneering the frontier of targeted mRNA-based in vivo gene therapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 961: August 25, 2023 <\/h4>\n

\"961-1\"\"961-2\"Steve Uden, M.D. and Martin Mackay, Ph.D.,<\/strong> Co-Founder and Chief Executive Officer of Rallybio and Co-Founder and Executive Chairman of Rallybio, on developing and delivering transformative therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 957: July 21, 2023<\/h4>\n

\"957\"Gregg Silverman, M.D., <\/strong> Professor of Medicine and Pathology at NYU School of Medicine, on discovering the link between lupus and the gut microbiome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 952: June 16, 2023 <\/h4>\n

\"952\"Joseph Kim,<\/strong> Chief Strategy Officer of ProofPilot, on pioneering the digital automation of antibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 949: May 26, 2023<\/h4>\n

\"947\"Matt Maisak, Ph.D.,<\/strong> CEO of Covant Therapeutics, on leading the way in developing novel therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 948: May 19, 2023 <\/h4>\n

\"943\"John K. Celebi,<\/strong> President and CEO of Sensei Biotherapeutics, Inc., on pioneering the frontier of VISTA-inhibiting antibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 947: May 12, 2023<\/h4>\n

\"947\"Rodney Varner,<\/strong> Co-founder, Chairman, and CEO of Genprex, Inc., on leveraging two novel gene therapies for cancer and diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 945: April 28, 2023<\/h4>\n

\"945\"Kenichiro Kuninobu, Ph.D.,<\/strong> Co-Founder and CEO of Feliqs, on developing a new drug targeting ferroptosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 943: April 14, 2023<\/h4>\n

\"943\"Dan Passeri, M.Sc., J.D.,<\/strong> CEO of Cue Biopharma, on developing the future of IL-2 therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 941: March 31, 2023<\/h4>\n

\"941\"Tony Reid, M.D., Ph.D.,<\/strong> CEO of EpicentRx Inc., on developing a very safe drug with multifaceted benefits.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 938: March 3, 2023<\/h4>\n

\"938\"Peter J. Chockley, PH.D,<\/strong> postdoctoral researcher at St. Jude Children’s Research Hospital, on optimizing the design of CARs with an anchoring protein.<\/p>\n<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 932: January 20, 2023<\/h4>\n

\"932\"David K. Barr, Esq.,<\/strong> Partner at Stroock & Stroock & Lavan LLP, on intellectual property complexities in cell and gene therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 931: January 13, 2023<\/h4>\n

\"931\"Chris Wasden, Ph.D.,<\/strong> Ameet Nathwani, M.D.,<\/strong> CEO of Dewpoint, on pioneering the frontier of condensate biology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 928: December 16, 2022<\/h4>\n

\"928\"Chris Wasden, Ph.D.,<\/strong> Chief Strategy Officer of Twill, on creating integrated care with digital therapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 927: December 9, 2022<\/h4>\n

\"927\"Lavi Erisson, M.D.,<\/strong> co-founder and CEO of Gensaic, on using phage as a delivery vector for gene therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issues 924 & 925: November 11 and November 17, 2022<\/h4>\n

\"924\"Mark Kessel<\/strong> Strategic Advisor to the Biopharma Sector, on structured financings for R&D programs in biotech companies and fulfilling the responsibilities of an outside board director in a special two part interview.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 922: October 28, 2022<\/h4>\n

\"922\"Daniela Salvemini, Ph.D.<\/strong> William Beaumont Professor and Chair Department of Pharmacology and Physiology Director, Henry and Amelia Nasrallah Center for Neuroscience Saint Louis University School of Medicine, on preventing chemotherapy-induced cognitive impairment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 921: October 21, 2022<\/h4>\n

\"921\"James A. Geraghty<\/strong> Author and Veteran of the Orphan Drug Field, on the frontlines of the orphan drug revolution.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 917: September 23, 2022<\/h4>\n

\"917\"Eitan S. Kaplan, Ph.D.,<\/strong> Scientific Project and Alliance Manager, the Allen Institute for Brain Science, on getting a comprehensive view of the brain to advance Alzheimer\u2019s research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 916: September 16, 2022<\/h4>\n

\"916\"Anand Parikh, J.D.,<\/strong> Chief Executive Officer and Co-Founder, Faeth Therapeutics, Inc., on depriving tumors of the nutrients they need to grow.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 915: Septembner 9, 2022<\/h4>\n

\"915\"John T. Schiller, Ph.D., <\/strong>Deputy Chief, Laboratory of Cellular Oncology, National Cancer Institute, NIH, on injecting tumors with a virus to promote robust T-cell tumor suppression.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 912: August 19, 2022<\/h4>\n

\"912\"Masanori Watanabe,<\/strong> Scohia Pharma Representative Director, President, CEO and CSO, on aiming to maximize the value of our assets through partnerships.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 908: July 22, 2022<\/h4>\n

\"908\"Arthur T. Sands, M.D., Ph.D.,<\/strong> President and CEO, Nurix Therapeutics, Inc., on opening up new horizons in oncology treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 907: July 15, 2022<\/h4>\n

\"907\"Jes\u00fas Martin-Garcia,<\/strong> Chairman, CEO, and Co-Founder, GeNeuro, on targeting pathogenic retroviral proteins.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 905: June 24, 2022<\/h4>\n

\"905\"Ping Wang, PhD, DABCC, FAACC,<\/strong> Founder and President, Instanosis Inc., Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, and Director of the Clinical Chemistry Section and Core Laboratory, University of Pennsylvania Perelman School of Medicine, on developing an ultrasensitive, rapid, and portable diagnostics platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 904: June 17, 2022<\/h4>\n

\"904\"Michael Watson, MB, ChB,<\/strong> Co-founder and CEO, Mevox Limited, on addressing the global lack of an effective mumps vaccine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 902: June 3, 2022<\/h4>\n

\"902\"Stephen Majors,<\/strong> Director, Public Affairs, Alliance for Regenerative Medicine, on developing regulatory and reimbursement standards for gene and cell therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 901: May 27, 2022<\/h4>\n

\"901\"John Glasspool,<\/strong> Chief Executive Officer, Anthos Therapeutics, on reducing the risk of thrombosis and the risk of bleeding.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 900: May 20, 2022<\/h4>\n

\"900\"Boro Dropuli\u0107, Ph.D.,<\/strong> Co-founder and Executive Director, Caring Cross, on making gene therapy more affordable and accessible.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 896: April 22, 2022<\/h4>\n

\"896\"Chris Hoyt,<\/strong> Chief Executive Officer, KeifeRx, LLC, on triggering autophagy to treat neurodegenerative diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 894: April 1, 2022<\/h4>\n

\"894\"David J. Arthur,<\/strong> Chief Executive Officer, Salarius Pharmaceuticals, Inc., on developing anti-cancer programs in protein inhibition and protein degradation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 893: March 25, 2022<\/h4>\n

\"893\"Nate Gross, M.D.,<\/strong> Co-Founder and Chief Strategy Officer, Doximity, on a digital platform tailored to the needs of doctors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 892: March 18, 2022<\/h4>\n

\"892\"Omid Veiseh, Ph.D.,<\/strong> Assistant Professor of Bioengineering and CPRIT Scholar in Cancer Research, Rice University, on localized administration of cytokine-producing cells to eradicate tumors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 891: March 11, 2022<\/h4>\n

\"891\"Tim Guilliams, Ph.D.,<\/strong> Co-Founder and Chief Executive, Healx, on combining AI with drug discovery expertise to treat rare diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 889: February 25, 2022<\/h4>\n

\"889\"Seiji Fujioka,<\/strong> Representative Director, Nitto Denko Avecia Inc., on growing alongside the nucleic acid medicine industry with a “Niche Top” strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 888: February 18, 2022<\/h4>\n

\"888\"James Sapirstein,<\/strong> Chief Executive Officer, First Wave Biopharma, on developing treatments for gastrointestinal disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 884: January 21, 2022<\/h4>\n

\"884\"Lane Weaver, Ph.D., <\/strong>Head of Strategy and Business Development, Novome Biotechnologies, Inc., on engineering bacteria in the gut microbiome to treat disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 880: December 17, 2021<\/h4>\n

\"880\"Lisa Ricciardi, <\/strong>Chief Executive Officer, Cognition Therapeutics, Inc., on targeting the sigma-2 receptor for CNS and ophthalmic disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 878: December 3, 2021<\/h4>\n

\"878\"Jennifer Buell, Ph.D., <\/strong>Chief Executive Officer, MiNK Therapeutics, on developing novel off-the-shelf cellular therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 877: November 19, 2021<\/h4>\n

\"877\"Aaron Sato, Ph.D., <\/strong>Chief Scientific Officer, Twist Bioscience Corporation, on making antibody discovery faster and more efficient.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 875: November 5, 2021<\/h4>\n

\"875\"Alessio Fasano, M.D., <\/strong>Director of the Center for Celiac Research and Treatment, Director of the Mucosal Immunology and Biology Research Center, and Division Chief of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, on uncovering the role of the microbiome in inflammatory diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 873: October 15, 2021<\/h4>\n

\"873\"Brian D. Gulbransen, Ph.D., <\/strong>Associate Professor of Physiology, Michigan State University, on exploring the functional roles of enteric glia.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 871: October 1, 2021<\/h4>\n

\"871\"Thanh Do, Ph.D., <\/strong>Assistant Professor, Department of Chemistry, the University of Tennessee, FCDI, on the relationship between migraine headaches and type 2 diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 870: September 24, 2021<\/h4>\n

\"870\"Mariko Tosu, Ph.D., <\/strong>Chairman, Braizon Therapeutics, on finding intel in the field of brain disease treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 869: September 17, 2021<\/h4>\n

\"869\"Takeshi Yamamoto, <\/strong>President and CEO, FCDI, on progress toward commercialization of regenerative medicine through a broad range of stem cell licenses.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 868: September 10, 2021<\/h4>\n

\"868\"Alexis M. Stranahan, Ph.D., <\/strong>Associate Professor, Department of Neuroscience and Regenerative Medicine, Medical College of Georgia at Augusta University, on how beige fat slows cognitive decline.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 866: August 27, 2021<\/h4>\n

\"866\"Matthew Stoudt, <\/strong>Co-Founder and CEO, AppliedVR, on using virtual reality to help patients manage chronic pain.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 865: August 20, 2021<\/h4>\n

\"865\"David Kelleher, <\/strong>Co-Founder and CEO, 4G Clinical, on making clinical trials faster and more efficient.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 864: August 13, 2021<\/h4>\n

\"864\"Eef Schimmelpennink, <\/strong>President and Chief Executive Officer, LENZ Therapeutics, on developing a treatment for presbyopia.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 856: June 18, 2021<\/h4>\n

\"856\"Steven Basta, <\/strong>CEO, Mahana Therapeutics, Inc., on a prescription digital therapeutic for irritable bowel syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 854: June 4, 2021<\/h4>\n

\"854\"Chase Coffman, Ph.D., <\/strong>CEO and Co-Founder, Electrofi, on using protein formulations to deliver biologics through simple injections.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 853: May 28, 2021<\/h4>\n

\"853a\"\"853b\"Kazuhiko Yamamoto, <\/strong>Co-founder and Director, BioPalette, and Kiyokazu Iwata, <\/strong>Business Development Manager, BioPalette, on developing biotherapeutics through base-editing of bacteria.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 851: May 14, 2021<\/h4>\n

\"851\"Sean A. McCarthy, D. Phil., <\/strong>President, CEO, and Chairman, CytomX Therapeutics, on engineering cancer therapeutics to avoid healthy tissue.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 849: April 30, 2021<\/h4>\n

\"849\"Per Hellsund, <\/strong>President and CEO, Cybrexa Therapeutics, on exploiting the acidity of tumors to deliver toxic payloads.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 848: April 23, 2021<\/h4>\n

\"848\"Fumihiko Urano, M.D., Ph.D., <\/strong>Professor of Internal Medicine and Pathology, University of Washington School of Medicine, and Founder of CURE4WOLFRAM, on focusing on gene therapy development as a treatment for optic atrophy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 846: April 9, 2021<\/h4>\n

\"846\"Aur\u00e9lie Grienenberger, Ph.D., <\/strong>Chief Business Officer, Eligo Bioscience, on precisely targeting the microbiome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 844: March 26, 2021<\/h4>\n

\"844\"Angela M. Reiersen, M.D., M.P.E., <\/strong>Associate Professor of Psychiatry, Washington University in St. Louis, on a repurposed drug showing efficacy in COVID-19 pateints.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 843: March 12, 2021<\/h4>\n

\"843\"Samuel Bakhoum, M.D., Ph.D., <\/strong>Assistant Member (Professor), Memorial Sloan Kettering Cancer Center, on targeting an untapped vulnerability of cancer cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 841: February 26, 2021<\/h4>\n

\"841\"Makoto Nakanishi, MD., Ph.D., <\/strong>Professor, Division of Cancer Cell Biology, Department of Cancer Biology, Institute of Medical Science, University of Tokyo, on the effects of GLS1 enzyme inhibition on controlling and improving aging.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 839: February 12, 2021<\/h4>\n

\"839\"Charles K. Fisher, Ph.D., <\/strong>Co-Founder and CEO, Unlearn.AI, on creating more efficient clinical trials with digital twins.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 836: January 22, 2021<\/h4>\n

\"836\"Peter Anthony Campochiaro, M.D., <\/strong>Director, Retinal Cell and Molecular Laboratory, Johns Hopkins University School of Medicine, on a better alternative to viral vectors for ocular gene therapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 832: December 18, 2020<\/h4>\n

\"832\"Mortimer Poncz, M.D., <\/strong>Chief of the Division of Hematology, Children’s Hospital of Philadelphia, on a novel treatment approach for sepsis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 831: December 11, 2020<\/h4>\n

\"831\"Paul Garofolo, <\/strong>President and Chief Executive Officer, Locus Biosciences, on a new platform for targeting bacteria.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 826: October 23, 2020<\/h4>\n

\"826\"Giovanni Traverso, M.B., B.Chir., Ph.D., <\/strong>Associate Physician, Brigham and Women’s Hospital, on lining the small intestine to modulate drug delivery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 821: September 18, 2020<\/h4>\n

\"821\"Anthony P. Mack, <\/strong>Founding Chairman and CEO, Virpax Pharmaceuticals, on developing non-addictive treatments for pain management.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 817: August 21, 2020<\/h4>\n

\"817\"Greg Merril, <\/strong>CEO and Co-Founder, Adaptive Phage Therapeutics, on developing the potential for phage therapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 814: July 31, 2020<\/h4>\n

\"814\"Takanori Kanai, M.D., Ph.D., <\/strong>Professor of Gastroenterology, Keio University School of Medicine, on elucidating a new mechanism of intestinal environment maintenance via vagus nerve reflexes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 813: July 24, 2020<\/h4>\n

\"813\"James Patterson, M.B., Ph.D., <\/strong>Founder, Auxolytic, on a novel safety switch for cell therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 803: May 8, 2020<\/h4>\n

\"803\"Fumihiko Urano, M.D., Ph.D., <\/strong>Professor of Internal Medicine and Pathology, University of Washington School of Medicine, on curing diabetes in mice with \u03b2 cells derived from gene-edited iPS cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 797: March 20, 2020<\/h4>\n

\"797\"Matt Coffey, Ph.D., <\/strong>Co-founder, President and Chief Executive Officer, Oncolytics Biotech Inc., on triggering an immune response against cancer with an oncolytic virus.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 795: March 6, 2020<\/h4>\n

\"795\"Evan Feinberg, Ph.D., <\/strong>CEO and Co-founder, Genesis Therapeutics, on using artificial intelligence and medicinal chemistry expertise to design optimized compounds.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 794: February 28, 2020<\/h4>\n

\"794\"Takuya Takahashi, MD. PhD, <\/strong>Professor of Physiology, Graduate School of Medicine, Yokohama City University, on imaging ampa receptors in human brains.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 793: February 21, 2020<\/h4>\n

\"793\"Vikas Sinha, <\/strong>Co-Founder and Chief Financial Officer, ElevateBio LLC, on building state-of-the-art production facilities for cell and gene therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 792: February 14, 2020<\/h4>\n

\"792\"Jennifer Radin, Ph.D., <\/strong>Senior Staff Scientist, Scripps Research Translational Institute, on using data from wearable sensors to track influenza.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 788: January 17, 2020<\/h4>\n

\"788\"Julie Fleshman, JD, MBA, <\/strong>President and CEO, the Pancreatic Cancer Action Network, on a platform for quickly and efficiently testing new pancreatic cancer treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 783: December 6, 2019<\/h4>\n

\"783\"Stephan Lammel, Ph.D., <\/strong>Assistant Professor of Neurobiology, Department of Molecular & Cell Biology University of California, Berkeley, on identifying the biology underlying specific symptoms of depression.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 782: November 22, 2019<\/h4>\n

\"782\"Josep Bassaganya-Riera, DVM, Ph.D., <\/strong>Chairman, President, and CEO, Landos Biopharma, Inc., on using novel metabolic pathways to treat autoimmune diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 781: November 15, 2019<\/h4>\n

\"781\"Michael Solomon, Ph.D., <\/strong>Chief Executive Officer, Ribometrix. Inc., on targeting the 3D structure of RNA to reach intractable targets.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 780: November 8, 2019<\/h4>\n

\"780\"Rob Etherington, <\/strong>President and CEO, Clene Nanomedicine, Inc., on addressing bioenergetic loss in neurodegenerative diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 778: October 25, 2019<\/h4>\n

\"778\"Haitao Hu, Ph.D., <\/strong>Assistant Professor, Microbiology & Immunology, University of Texas Medical Branch, on small molecule induced epigenetic suppression of HIV.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 775: October 4, 2019<\/h4>\n

\"775\"Laura Towart Bandak, <\/strong>Founder and CEO, My Personal Therapeutics, on using fruit flies to screen for personalized cancer treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 774: September 27, 2019<\/h4>\n

\"774\"Othman Laraki, <\/strong>Co-Founder and CEO, Color, on providing genetic information at scale for low cost.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 773: September 20, 2019<\/h4>\n

\"773\"Albert Garcia-Romeu, Ph.D., <\/strong>Instructor in Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, on exploring the therapeutic potential of psilocybin.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 772: September 13, 2019<\/h4>\n

\"772\"Amit Kumar, Ph.D., <\/strong>Chairman, President and CEO, Anixa Biosciences, on the development of a vaccine designed to prevent triple-negative breast cancer.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 770: August 30, 2019<\/h4>\n

\"770\"Karl Bergman, <\/strong>CEO, Elypta, on metabolic biomarkers as a tool for cancer detection.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 769: August 23, 2019<\/h4>\n

\"769\"Adam P. Croft. MRCP, Ph.D., <\/strong>NIHR Academic Clinical Lecturer in Rheumatology, Institute of Inflammation and Ageing, University of Birmingham and Queen Elizabeth Hospital, on identifying drivers of inflammation and joint damage in arthritis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 767: August 9, 2019<\/h4>\n

\"767\"David H. Donabedian, Ph.D., <\/strong>Co-founder and CEO, Axial Biotherapeutics, on focusing on the gut-brain axis for neurological diseases and beyond.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 765: July 26, 2019<\/h4>\n

\"765\"Daniel S. Kohane, M.D., Ph.D., <\/strong>Senior Associate in Critical Care; Director, Laboratory for Biomaterials and Drug Delivery Boston Children\u2019s Hopital, and Professor of Anesthesiology, Harvard Medical School, on creating a safe and long-lasting local anesthetic.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 764: July 19, 2019<\/h4>\n

\"764\"S. Roy Kimura, Ph.D., <\/strong>Co-founder and CEO, Modulus Discovery, Inc., on discovering revolutionary treatments through virtual pharma.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 761: June 21, 2019<\/h4>\n

\"761\"John Didsbury, Ph.D., <\/strong>Founder and CEO, T3D Therapeutics, Inc., on correcting glucose metabolism to treat Alzheimer\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 760: June 14, 2019<\/h4>\n

\"760\"Miguel A. Pappolla, M.D., Ph.D., <\/strong>Professor of Neurology, University of Texas Medical Branch, on making a connection between insulin resistance and fibromyalgia.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 758: May 31, 2019<\/h4>\n

\"758\"Andrew A. Radin, <\/strong>CEO and Co-Founder, twoXAR, on separating interesting work from hype in AI-based drug discovery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 757: May 24, 2019<\/h4>\n

\"757\"Anthony Slonim, MD, DrPH, <\/strong>President and Chief Executive Officer, Renown Health, on creating a data warehouse for population health on a grand scale.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 755: May 10, 2019<\/h4>\n

\"755\"Berislav V. Zlokovic, M.D., Ph.D., <\/strong>Director of the Zilkha Neurogenetic Institute and Professor and Chair of the Department of Physiology & Neuroscience, Keck School of Medicine, University of Southern California, on reducing beta amyloid accumulation with 3K3A-APC.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 753: April 26, 2019<\/h4>\n

\"753\"Mir Imran, <\/strong>Chairman and CEO, Rani Therapeutics, on devising a pill to deliver biologics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 748: March 22, 2019<\/h4>\n

\"748\"Alain Vicari, D.V.M., Ph.D., <\/strong>CEO and Co-founder, Calypso Biotech, on targeting IL-15 for eosinophilic esophagitis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 744: February 15, 2019<\/h4>\n

\"744\"Philippe P. Calais, Pharm. D., Ph.D., <\/strong>Chief Executive Office, CohBar, Inc., on mitochondria-based therapeutics to treat age-related diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 742: February 1, 2019<\/h4>\n

\"742\"Jason M. Peters, Ph.D., <\/strong>Assistant Professor, University of Wisconsin\u2013Madison School of Pharmacy, on understanding gene function in diverse bacteria using Mobile-CRISPRi.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 739: January 11, 2019<\/h4>\n

\"739\"Zhen Gu, Ph.D., <\/strong>Professor, Department of Bioengineering and the California NanoSystems Institute, University of California, Los Angeles, on inhibiting cancer recurrence and metastasis after surgery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 735: December 7, 2018<\/h4>\n

\"735\"Nader Z. Pourhassan, Ph.D., <\/strong>President and CEO, CytoDyn Inc., on blocking CCR5 in HIV, oncology, and autoimmune diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 734: November 30, 2018<\/h4>\n

\"734\"Edward Cox, <\/strong>Chief Executive Officer, Dthera Sciences, on triggering faint memories to reduce agitation and depression.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 733: November 16, 2018<\/h4>\n

\"733\"Benjamin A. Plog, Ph.D., <\/strong>CCenter for Translational Neuromedicine, University of Rochester, on using the glymphatic system to deliver drugs deep into the brain.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 732: November 9, 2018<\/h4>\n

\"732\"C. Boyd Clarke, <\/strong>Executive Chairman, FluGen, Inc., on preventing influenza virus replication.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 730: October 26, 2018<\/h4>\n

\"730\"Tanaka Masato, M.D., <\/strong>Professor, Laboratory of Immune Regulation, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, on discovering monocytes limiting new inflammation that emerge in inflammation recovery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 729: October 19, 2018<\/h4>\n

\"729\"George Tetz, M.D., Ph.D.,<\/strong> CEO of the Human Microbiology Institute, on bacteriophages implicated in triggering Parkinson\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 726: September 28, 2018<\/h4>\n

\"726a\"\"726b\"Christopher Heise, Ph.D., <\/strong>Associate Director, Genentech, and Peter Smith, Ph.D., <\/strong>Scientist, Genentech, on developing effective new compounds for attacking Gram-negative bacteria.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n

Issue 721: August 24, 2018<\/h4>\n

\"721\"Yochi Slonim, <\/strong>Founder and CEO, Anima Biotech, on modulating the production of proteins to treat disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 720: August 17, 2018<\/h4>\n

\"720\"Misti Ushio, Ph.D., <\/strong>Chief Executive Officer, TARA Biosystems, on engineering mature cardiac tissue for high-throughput applications.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 717: July 20, 2018<\/h4>\n

\"717\"Mike Romanos, Ph.D., <\/strong>Co-founder and Chief Executive Officer, Microbiotica Limited, on characterizing the microbiome to create bacteria as therapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 716: July 13, 2018<\/h4>\n

\"716\"Yasuhiko Idaka, <\/strong>Representative Director, Yakushin Co., Ltd., on how pharmaceutical companies should compete in the rapidly changing Japanese market.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 713: June 15, 2018<\/h4>\n

\"713\"Takuya Takahashi, M.D., <\/strong>Professor, Department of Physiology, Yokohama City University, on discovering compounds promoting plastic change in the brain.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 711: June 1, 2018<\/h4>\n

\"711\"Peter Kirk, <\/strong>Chief Executive Officer, SERMO, on a platform for doctors to share knowledge with each other.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 709: May 18, 2018<\/h4>\n

\"709\"Paul Wotton, Ph.D., <\/strong>Chief Executive Officer, Sigilon Therapeutics, on implanting encapsulated cells to treat chronic diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 706: April 27, 2018<\/h4>\n

\"706\"Art Krieg, M.D., <\/strong>Founder and CEO, Checkmate Pharmaceuticals, on synergistic therapy to enhance responses to checkpoint inhibitors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 704: April 13, 2018<\/h4>\n

\"704\"Wendy S. Rubinstein, M.D., Ph.D., <\/strong>Deputy Medical Director, CancerLinQ LLC, on learning from real-world data to improve cancer care.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 703: April 6, 2018<\/h4>\n

\"703\"Bernat Olle, Ph.D., <\/strong>Chief Executive Officer, Vedanta Biosciences, Inc., on modulating the microbiome with consortia of bacteria to treat disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 702: March 29, 2018<\/h4>\n

\"702\"Edward Giniger, Ph.D., <\/strong>Senior Investigator, National Institute of Neurological Disorders and Stroke, on premature aging in neurodegenerative diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 697: February 23, 2018<\/h4>\n

\"697\"Jean-Simon Diallo, Ph.D., <\/strong>Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, on inhibiting NF-\u03baB to enhance the effectiveness of oncolytic viral therapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 696: February 16, 2018<\/h4>\n

\"696\"Thomas G. Evans, M.D., <\/strong>Chief Executive Officer, Vaccitech Limited, on developing a universal influenza vaccine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 693: January 26, 2018<\/h4>\n

\"693\"Steve Carchedi, <\/strong>Chief Executive Officer, Apexian Pharmaceuticals, Inc., on targeting tumors while protecting neurons.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 692: January 19, 2018<\/h4>\n

\"692\"Scott Koenig, M.D., Ph.D., <\/strong>President and CEO, MacroGenics, Inc., on dampening B cell activation without depleting B cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 691: January 12, 2018<\/h4>\n

\"691\"Masahisa Ikeda, <\/strong>Shearman & Sterling, on people as the key to the global expansion of Japanese companies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 689: December 22, 2017<\/h4>\n

\"689\"David Kita, Ph.D., <\/strong>Co-Founder and Vice President of R&D, Verseon Corporation, on modeling a more diverse chemical space for drug discovery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 686: December 1, 2017<\/h4>\n

\"686\"Alice Zhang, <\/strong>Chief Executive Officer and Co-founder, Verge Genomics, on an integrated approach to accelerate drug discovery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 682: October 27, 2017<\/h4>\n

\"682\"Kevin Outterson, <\/strong>Executive Director, CARB-X, on accelerating R&D in new antibiotics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 681: October 20, 2017<\/h4>\n

\"681\"Lucas Nivon, Ph.D., <\/strong>Chief Executive Officer, Cyrus Biotechnology, Inc., on bringing the power of Rosetta to a broad base of users.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 679: October 6, 2017<\/h4>\n

\"679\"John Sullivan-Bolyai, M.D., <\/strong>Chief Medical Officer, ContraVir Pharmaceuticals, Inc., on developing combination treatments for the hepatitis B virus.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 678: September 29, 2017<\/h4>\n

\"678\"Sean F. Brady, Ph. D., <\/strong>Evnin Associate Professor and Head, Laboratory of Genetically Encoded Small Molecules, Rockefeller University, on exploring potential interactions between the microbiome and human cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 677: September 22, 2017<\/h4>\n

\"677\"Vishwanath R. Lingappa, M.D., Ph.D., <\/strong>Chief Executive Officer, Prosetta Biosciences, Inc., on targeting aberrant assembly machines.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 675: September 8, 2017<\/h4>\n

\"675\"Robert C. Doebele, M.D., Ph.D., <\/strong>Associate Professor, University of Colorado Anschutz Medical Campus, on using depth of initial treatment response as an indicator of outcomes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 673: August 25, 2017<\/h4>\n

\"673\"Junken Aoki, Pharm.D., <\/strong>Professor of Molecular and Cellular Biochemistry, Tohoku University Graduate School of Pharmaceutical Sciences, on Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 671: August 11, 2017<\/h4>\n

\"671\"Ryan Sysko, <\/strong>CEO and Founder, Amalgam Rx, Inc., on delivering better health outcomes with apps.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 669: July 28, 2017<\/h4>\n

\"669\"Mark Swindells, Ph.D., <\/strong>Chief Operating Officer, Exscientia, Ltd., on automating drug design.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 668: July 21, 2017<\/h4>\n

\"668a\"\"668b\"Amy Schulman, <\/strong>Co-Founder and Chief Executive Officer, and Jessica Ballinger, <\/strong>Vice President of Reimbursement and Strategic Alliances, Lyndra, Inc., on moving from daily dosing to weekly dosing and beyond.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 667: July 14, 2017<\/h4>\n

\"667\"David Merryman, Ph.D., <\/strong>Associate Professor of Biomedical Engineering, Pharmacology, Medicine, and Pediatrics, and  Associate Chair of Biomedical Engineering, Vanderbilt University, on blocking cadherin-11 as a potential treatment for calcific aortic valve disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 664: June 16, 2017<\/h4>\n

\"664\"Noah Craft, MD, PhD, DTMH, <\/strong>Co-Founder and CEO, Science 37, on bringing clinical trials to the homes of patients.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 660: May 19, 2017<\/h4>\n

\"660\"Michael Levin, Ph.D., <\/strong>Professor, Vannevar Bush Chair, and Director, Allen Discovery Center at Tufts University, and Tufts Center for Regenerative and Developmental Biology, on treating atopic dermatitis through autografts of benign bacteria.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 657: April 28, 2017<\/h4>\n

\"657a\"\"657b\"Robert McNeil, Ph.D., <\/strong>Chief Executive Officer, and Donald M. Black, M.D., <\/strong>Chief Medical Officer, DalCor Pharmaceuticals, on exploring the limits of brain plasticity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 656: April 21, 2017<\/h4>\n

\"656\"Teruaki Nakatsuji, Ph.D., <\/strong>Project Scientist, Department of Dermatology, UC San Diego School of Medicine, on treating atopic dermatitis through autografts of benign bacteria.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 655: April 7, 2017<\/h4>\n

\"655\"Milton H. Werner, Ph.D., <\/strong>Founder, President, and CEO, Inhibikase Therapeutics, on developing a disease modifying treatment for Parkinson\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 654: March 31, 2017<\/h4>\n

\"654\"Michael Snyder, Ph.D., <\/strong>Stanford W. Ascherman Professor and Chair, Department of Genetics, and Director, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, on bringing wearable devices into clinical use.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 653: March 24, 2017<\/h4>\n

\"653\"Pierre Beauparlant, Ph.D., <\/strong>Chief Business Officer, Diazon Pharmaceuticals Inc., on developing a potent microtubule-targeting agent with less toxicity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 651: March 10, 2017<\/h4>\n

\"651\"Michael Hooven, <\/strong>President and CEO, Enable Injections, Inc., on improving the way biologics are delivered.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 649: February 24, 2017<\/h4>\n

\"649\"Jay Yourist, Ph.D., <\/strong>President & Chief Executive Officer, Nuovo Biologics LLC, on developing treatments for animals, and possibly humans.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 648: February 17, 2017<\/h4>\n

\"648\"Tim Errington, Ph.D., <\/strong>Metascience Manager, Center for Open Science, on the difficulties of reproducing research results.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 646: February 3, 2017<\/h4>\n

\"646\"Stanley Kim, <\/strong>Co-founder and CEO, WinSanTor, Inc., on restoring sensory fibers in peripheral neuropathy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 644: January 20, 2017<\/h4>\n

\"644\"Keith Murphy, <\/strong>Chairman and Chief Executive Officer, Organovo Holdings, Inc., on engineering human tissues for pharmaceutical screening.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 643: January 13, 2017<\/h4>\n

\"643\"Catharina Boehme. M.D., <\/strong>Chief Executive Officer, Foundation for Innovative New Diagnostics, on developing diagnostics for poverty-related diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 641: December 23, 2016<\/h4>\n

\"641\"Geoff MacKay, <\/strong>President and CEO, AvroBio, Inc., on quickly bringing novel gene therapies into the clinic.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 640: December 16, 2016<\/h4>\n

\"640a\"\"640b\"Ted Yednock, Ph.D., <\/strong>Chief Scientific Officer, and Douglas Love, <\/strong>President and CEO, Annexon Biosciences, on targeting the complement pathway in neurodegenerative diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 639: December 9, 2016<\/h4>\n

\"639\"Linda Summerton, Ph.D., <\/strong>CEO, Immodulon Therapeutics Ltd., on triggering the immune system to fight cancer with mycobacteria.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 638: December 2, 2016<\/h4>\n

\"638\"Aftab Ansari, Ph.D., <\/strong>Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, and Research Professor, Yerkes National Primate Research Center, on opening the potential for sustained control of HIV infection.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 637: November 18, 2016<\/h4>\n

\"637\"Jack W. Reich, Ph.D., <\/strong>CEO and Co-founder, Renova Therapeutics, on gene therapy to normalize heart function in heart failure patients.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 634: October 28, 2016<\/h4>\n

\"634\"Alex Haahr Gouliaev, Ph.D., <\/strong>Co-founder and Chief Executive Officer, Nuevolution AB, on efficiently identifying small-molecule drug candidates for difficult targets.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 632: October 14, 2016<\/h4>\n

\"632\"Sylvain Martel, Ph.D., <\/strong>Professor and Director, NanoRobotics Laboratory, Department of Computer and Software Engineering, Institute of Biomedical Engingeering, Polytechnique, on delivering drugs to the optimal location inside tumors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 631: October 7, 2016<\/h4>\n

\"631\"Sau (Larry) Lee, Ph.D., <\/strong>Deputy Director (Acting), Office of Testing and Research, Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research, FDA, on encouraging industry adoption of continuous manufacturing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 629: September 23, 2016<\/h4>\n

\"629a\"\"629b\"Gergely T\u00f3th, Ph.D., M.B.A., <\/strong>Founder and Chief Executive Officer, and Thomas Sawyer, Ph.D., M.B.A.,<\/strong> Chief Operations Officer, Cantabio Pharmaceuticals Inc., on pursuing novel treatment strategies for neurodegenerative diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 628: September 16, 2016<\/h4>\n

\"628\"Andrew M. Radin, <\/strong>Chief Business Officer & Co-Founder, TwoXAR, on using predictive algorithms to identify novel drug candidates.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 627: September 9, 2016<\/h4>\n

\"627\"Jack A. Syage, Ph.D., <\/strong>CEO and Co-founder, ImmunogenX, on developing a treatment and diagnostic tools for celiac disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 625: August 26, 2016<\/h4>\n

\"625\"Dane M. Chetkovich, M.D., Ph.D., <\/strong>Professor of Neurology and Physiology, Northwestern University Feinberg School of Medicine, on a new potential drug target for the treatment of depression.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 623: August 12, 2016<\/h4>\n

\"623\"Christian Tidona, Ph.D., <\/strong>Managing Director, BioMed X Innovation Center, on creating innovative research teams to collaborate with industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 621: July 29, 2016<\/h4>\n

\"621\"Anthony J. Filiano, Ph.D., <\/strong>Postdoctoral Researcher, Center for Brain Immunology and Glia, School of Medicine, University of Virginia, on uncovering the connections between the immune system, brain circuits, and behavior.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 618: July 8, 2016<\/h4>\n

\"618\"Bharatt Chowrira, Ph.D., J.D., <\/strong>President, Synlogic, on developing programmable probiotics as a novel class of therapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 617: June 24, 2016<\/h4>\n

\"617\"Layton Smith, Ph.D., <\/strong>Assistant Professor and Director, Florida Drug Discovery, the Florida Translational Research Program at the Sanford Burnham Prebys Medical Discovery Institute, on advancing the frontiers of academic drug discovery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 616: June 17, 2016<\/h4>\n

\"616\"Charles Swanton, FRCP, Ph.D., <\/strong>Group Leader, the Francis Crick Institute, on understanding tumor evolution to develop better treatment strategies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 612: May 13, 2016<\/h4>\n

\"612\"Jean-Fran\u00e7ois Mouney, <\/strong>CEO and Chairman, GENFIT, on positioning Elafibranor as a first-line treatment in NASH.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 610: April 29, 2016<\/h4>\n

\"610\"Joseph S. Beckman, Ph.D., <\/strong>Principal Investigator and Burgess and Elizabeth Jamieson Chair in Healthspan Research, Linus Pauling Institute, Distinguished Professor, Department of Biochemistry and Biophysics, and Director, Environmental Health Sciences Center, Oregon State University, on preclinical breakthroughs in ALS now heading into the clinic.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 609: April 22, 2016<\/h4>\n

\"609\"Pablo Graiver, <\/strong>Founder and CEO, TrialReach, on making it easy for patients to connect to clinical trials.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 608: April 15, 2016<\/h4>\n

\"608\"Guoping Feng, Ph.D., <\/strong>Investigator, McGovern Institute for Brain Research, and Poitras Professor of Neuroscience, MIT, and Director, Model Systems and Neurobiology, Stanley Center for Psychiatric Research at the Broad Institute, on uncovering the mechanisms underlying autism spectrom disorder.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 603: March 11, 2016<\/h4>\n

\"603\"Robert Masella, <\/strong>Partner, Shearman & Sterling, on the outlook for M&A activity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 602: March 4, 2016<\/h4>\n

\"602\"William Flavahan, Ph.D., <\/strong>Postdoctoral Fellow, Massachusetts General Hospital and Harvard Medical School, on new insights into oncogene activation in IDH mutant gliomas.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 601: February 26, 2016<\/h4>\n

\"601\"Niven R. Narain, <\/strong>Co-Founder, President & Chief Executive Officer, Berg LLC, on integrating big data to drive drug discovery and development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 600: February 19, 2016<\/h4>\n

\"600\"Apkar Vania Apkarian, Ph.D., <\/strong>Professor of Physiology, Northwestern University Feinberg School of Medicine, on reversing the remodeling of the brain associated with chronic pain.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 599: February 12, 2016<\/h4>\n

\"599\"Jon Palfreman, Ph.D., <\/strong>author of Brain Storms, on tracking research developments in Parkinson\u2019s, now as a patient.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 595: January 15, 2016<\/h4>\n

\"595\"David Fellows, <\/strong>Chief Executive Officer and Board Member, NightstaRx Ltd., on developing gene therapies for inherited retinal dystrophies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 592: December 11, 2015<\/h4>\n

\"592\"Dallas E. Hughes, Ph.D., <\/strong>President, NovoBiotic Pharmaceuticals, LLC, on developing a platform for discovering new classes of antibiotics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 590: November 20, 2015<\/h4>\n

\"590\"Minoru Takasato, Ph.D.,<\/strong> Senior Researcher at the Murdoch Childrens Research Institute, on creating a kidney organoid that contains all human kidney cell types.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 589: November 13, 2015<\/h4>\n

\"589\"Joseph S. McCracken, D.V.M., <\/strong>Vice President of Business Development, Alkahest, Inc., on using young plasma to treat Alzheimer\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 588: November 6, 2015<\/h4>\n

\"588\"Jeffrey S. Mogil, Ph.D., <\/strong>E.P. Taylor Professor of Pain Studies and Canada Research Chair in Genetics of Pain (Tier I) at McGill University, on the increasing placebo response over time in US clinical trials of neuropathic pain.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 585: October 9, 2015<\/h4>\n

\"585\"Margarita Behrens, Ph.D., <\/strong>Staff Scientist, Salk Institute for Biological Studies, on the role of mGluR5 in the development of parvalbumin-positive interneurons and neurodevelopmental disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 584: October 2, 2015<\/h4>\n

\"584\"Kang Zhang, M.D., Ph.D., <\/strong>Professor of Ophthalmology and Chief of Ophthalmic Genetics, University of California, San Diego, on reversing cataracts with lanosterol.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 583: September 25, 2015<\/h4>\n

\"583\"Thomas West, <\/strong>Project Director and Manager of Intellectual Property, Aprecia Pharmaceuticals Company, on a novel formulation to improve adherence for those with difficulty swallowing pills.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 581: September 11, 2015<\/h4>\n

\"581\"Nathalie Donne, <\/strong>Director of Corporate Communication & Business Development, DBV Technologies, on meeting unmet needs in severe food allergies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 579: August 28, 2015<\/h4>\n

\"579\"Greg Duncan, <\/strong>President and Chief Executive Officer, Celtaxsys, Inc., on downregulating the neutrophil response in inflammatory disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 578: August 21, 2015<\/h4>\n

\"578\"Alexis C. Wallace, <\/strong>Co-founder, President, and Chief Executive Officer, Thrombolytic Science International, LLC, on extending the treatment window for stroke with greater safety.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 576: August 7, 2015<\/h4>\n

\"576\"Tsuyoshi Inoue, PharmD, <\/strong>Associate Professor, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, on developing epilepsy treatment targeting the LDH metabolic enzyme.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 574: July 24, 2015<\/h4>\n

\"574\"Luis A. Diaz, Jr., M.D., <\/strong>Associate Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, on mismatch repair deficiency and response to PD-1 inhibitors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 572: July 10, 2015<\/h4>\n

\"572\"Ted J. Kaptchuk, <\/strong>Professor of Medicine, Harvard Medical School, on investigating the genetic components of the placebo effect.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 571: June 26, 2015<\/h4>\n

\"571\"Pascale Malgouyres, Pharm D, MSc, <\/strong>Chief Commercial Officer and Co-Founder, Poxel SA, on developing a pipeline of novel treatments for type 2 diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 569: June 12, 2015<\/h4>\n

\"569\"Charles Magness, Ph.D., <\/strong>President and CEO, Kineta, Inc., on building a more efficient model of early-stage drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 567: May 29, 2015<\/h4>\n

\"567\"Andrew Vaillant, Ph.D., <\/strong>Chief Scientific Officer, RepliCor, on developing new treatments for Hepatitis B focused on subvirus particles.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 566: May 22, 2015<\/h4>\n

\"566\"Konrad Glund, Ph.D., <\/strong>Co-founder and CEO, Probiodrug AG, on moving from research discovery to clinical development in Alzheimer\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 565: May 15, 2015<\/h4>\n

\"565\"Ra\u00fal Insa, M.D., Ph.D.,<\/strong> Founder & CEO, SOM Biotech SL, on screening existing drugs for new indications.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 564: May 8, 2015<\/h4>\n

\"564\"William Moore., Ph.D., <\/strong>President and CEO, Innocrin Pharmaceuticals, Inc., on developing a new class of CYP17 lyase inhibitors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 562: April 24, 2015<\/h4>\n

\"562\"Jos Joore, Ph.D., <\/strong>Co-founder and Chief Business Officer, Mimetas B.V., on building high-throughput organs-on-chips.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 560: April 10, 2015<\/h4>\n

\"560\"Rudolph E. Tanzi, Ph.D.<\/strong>, Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School, and Director, Genetics and Aging Research Unit, Massachusetts General Hospital, and Doo Yeon Kim, Ph.D.,<\/strong> Assistant Professor of Neurology, Harvard Medical School, and Assistant in Neurology, Genetics and Aging Research Unit, Massachusetts General Hospital, on a new and better preclinical model of Alzheimer\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 559: April 2, 2015<\/h4>\n

\"559\"Alexey Terskikh, Ph.D.,<\/strong> Associate Professor, Sanford-Burnham Medical Research Institute, on developing a treatment to regrow hair.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 557: March 20, 2015<\/h4>\n

\"557\"Ali Tehrani, Ph.D.,<\/strong> President & Chief Executive Officer, Zymeworks Inc., on demonstrating success with bispecific antibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 556: March 13, 2015<\/h4>\n

\"556\"Todd C. Brady, M.D., Ph.D., <\/strong>President and CEO, Aldeyra Therapeutics, Inc., on an aldehyde trap to treat inflammatory and other diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 555: March 6, 2015<\/h4>\n

\"555\"Brian M. Culley, <\/strong>Chief Executive Officer, Mast Therapeutics, Inc., on developing vepoloxamer for sickle cell disease and other indications.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 553: February 20, 2015<\/h4>\n

\"553\"Cedric Francois, M.D., Ph.D., <\/strong>Co-founder & Chief Executive Officer, Apellis Pharmaceuticals, Inc., on being in the clinic with complement immunotherapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 552: February 13, 2015<\/h4>\n

\"552\"Norikazu Eiki, <\/strong>Former Chairman, Bayer Yakuhin, on breaking through the status quo with revolutionary business models.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 550: January 30, 2015<\/h4>\n

\"550\"Alexander Green, Ph.D.,<\/strong> Assistant Professor, Department of Chemistry & Biochemistry, Arizona State University, on the design and application of toehold switches.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 549: January 23, 2015<\/h4>\n

\"549\"Keith Blackwell, M.D., Ph.D., <\/strong>Associate Research Director, Joslin Diabetes Center, Professor, Department of Genetics, Harvard Medical School, and Faculty Member, Harvard Stem Cell Institute, on identifying biomarkers of longevity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 547: January 9, 2015<\/h4>\n

\"547\"Saad A. Naseer, M.D., <\/strong>President and CEO, The Jack and J.T Snow Scientific Research Foundation, on developing a potential treatment for Wolfram syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 544: December, 2014<\/h4>\n

\"544\"Dendy Young, <\/strong>Chairman, Co-Founder and CEO, Perthera, on building an expert system for personalized cancer treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 543: December 5, 2014<\/h4>\n

\"543\"Holly Trautman, PharmD, MS,<\/strong> Co-founder, Aventine Consulting, LLC, on getting reimbursement dossiers right.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 541: November 14, 2014<\/h4>\n

\"541\"Christoph Lengauer, Ph.D.,<\/strong> Chief Scientific Officer, Blueprint Medicines, on building a pipeline of novel kinase inhibitors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 539: October 31, 2014<\/h4>\n

\"539\"Richard A. Bendis,<\/strong> President and CEO, BioHealth Innovation, Inc., on building a more vibrant life sciences cluster in Maryland.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 536: October 10, 2014<\/h4>\n

\"536\"Johan Pontin,<\/strong> CEO, Beryllium, on making an impact in drug discovery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 535: October 3, 2014<\/h4>\n

\"535\"Julia P. Gregory<\/strong>, Chief Executive Officer, ContraFect Corporation, on developing novel approaches for treating infectious diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 534: September 26, 2014<\/h4>\n

\"534\"Jeffrey Stein, Ph.D.,<\/strong> President and CEO, Cidara Therapeutics, Inc., on addressing unmet needs in infectious diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 533: September 19, 2014<\/h4>\n

\"533\"R.J. Tesi, M.D.<\/strong>, President and CEO, FPRT Bio, on targeting neuroinflammation with a selective TNF inhibitor.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 532: September 12, 2014<\/h4>\n

\"532\"Dario C. Altieri<\/strong>, Executive Vice President, The Wistar Institute, Director and Chief Scientific Officer, The Wistar Cancer Center, and Robert and Penny Fox Distinguished Professor of Cancer Biology, on unraveling the role of TRAP-1 in cell metabolism and tumor biology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 530: August, 29, 2014<\/h4>\n

\"530\"Paul J. Lombroso, M.D.,<\/strong> Elizabeth Mears and House Jameson Professor in the Child Study Center, Professor of Neurobiology and of Psychiatry, and Director of the Laboratory of Molecular Neurobiology, Yale University School of Medicine, on inhibiting STEP as a potential treatment for Alzheimer\u2019s Disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 529: August 22, 2014<\/h4>\n

\"529\"Bruce M. Spiegelman,<\/strong> Ph.D.,<\/strong> Stanley J. Korsmeyer Professor of Cell Biology and Medicine, Department of Cell Biology, Harvard Medical School, and Professor, Cancer Biology, Dana-Farber Cancer Institute, on prospects for a potential treatment for cancer cachexia by using tumour-derived parathyroid-hormone-related proteins.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 528: August 8, 2014<\/h4>\n

\"528\"Eiji Yoshihara, Ph.D.,<\/strong> Salk Institute for Biological Studies, on the significance of the institute\u2019s research in the development of recombinant fibroblast growth factor 1 for the effective treatment of Type 2 Diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 525: July 18, 2014<\/h4>\n

\"525\"Jon Meyer,<\/strong> Principal and Co-founder, Life Science Strategy Group, LLC, on launching the new OutsourcePharma Advisory Board, an anonymized social networking site that provides crowd-sourced reviews of the services of CROs for contract research outsourcing professionals at pharmaceutical companies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 524: July 11, 2014<\/h4>\n

\"524\"Allan Bradley, Ph.D.,<\/strong> Founder and Chief Technical Officer, Kymab Limited, on his company\u2019s Kymouse transgenic antibody platform, development programs for fully human monoclonal drugs, and partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 523: June 27, 2014<\/h4>\n

\"523\"Rahul Aras, Ph.D.,<\/strong> President and Chief Executive Officer, Juventas Therapeutics, Inc., on developing a pipeline of therapies focused on the treatment of heart failure, and his company\u2019s lead development program and partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 521: June 13, 2014<\/h4>\n

\"521\"Steve Orndorff, Ph.D.,<\/strong> President and CEO, MicroBiome Therapuetics, LLC, on his company\u2019s clinical development programs and approach to developing prebiotics to alter the microbiome in the treatment of a variety of diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 519: May 30, 2014<\/h4>\n

\"519\"Jennifer Doudna, Ph.D.,<\/strong> Professor, Molecular and Cell Biology Department and Chemistry Department, University of California, Berkeley, Investigator, Howard Hughes Medical Institute, and Faculty Scientist, Lawrence Berkeley National Laboratory, on current research and potential future applications of the CRISPR-Cas system.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 518: May 23, 2014<\/h4>\n

\"518\"Jianghong Rao, Ph.D.,<\/strong> Associate Professor of Radiology, School of Medicine, Stanford University, on using a nanoparticle that can detect reactive oxygen species and reactive nitrogen species in vivo that could lead to improved methods for liver toxicity testing of drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 517: May 16, 2014<\/h4>\n

\"517\"Shivaani Kummar, M.D.,<\/strong> Head, Developmental Therapeutics Clinic, National Cancer Institute, on the clinical trial Molecular Profiling based Assignment of Cancer Therapeutics (M-PACT), which determines whether selecting therapies based on genetic mutations can improve outcomes in patients with metastatic sold tumors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 513: April 17, 2014<\/h4>\n

\"513\"Mark Kessel,<\/strong> Co-founder, Symphony Capital, on employing a new structure for financing drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 512: April 11, 2014<\/h4>\n

\"512\"Adam Gazzaley, M.D., Ph.D.,<\/strong> Associate Professor of Neurology, UCSF School of Medicine, on developing a video game to assess and improve cognitive performance.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 510: March 28, 2014<\/h4>\n

\"shuhologo\"Lyndon Lien, Ph.D.,<\/strong> President and CEO of Balance Therapeutics, Inc., on reducing inhibitory signaling as an approach to improving cognitive performance in Down syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 508: March 14, 2014<\/h4>\n

\"508\"John O\u2019Rourke,<\/strong> Vice President of Marketing, Decisyon, Inc., on bringing together people and data to make and execute decisions.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 507: March 7, 2014<\/h4>\n

\"507\"Craig M. Crews, Ph.D.,<\/strong> Founder and Chief Scientific Advisor of Arvinas, Inc., and Professor, Yale University, using novel platforms to develop small molecules that can induce the degradation of disease-causing proteins.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 505: February 21, 2014<\/h4>\n

\"505\"Warren Hosseinion, M.D.,<\/strong> CEO of Apollo Medical Holdings, Inc., partnering to improve patient care in COPD.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 502: January 31, 2014<\/h4>\n

\"shuhologo\"Michael Conn, Ph.D.,<\/strong> Senior Vice President for Research, Associate Provost and Professor of Internal Medicine and Cell Biology, Texas Tech University Health Sciences Center, on using pharmacoperones to fix misfolded proteins.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 501: January 24, 2014<\/h4>\n

\"501\"Yukinori Okada M.D., Ph.D.,<\/strong> tenure-track lecturer at Tokyo Medical and Dental University, Department of Human Genetics and Disease Diversity, on seeking new possibilities of genome drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 500: January 17, 2014<\/h4>\n

\"500\"Warner C. Greene, M.D., Ph.D.,<\/strong> Director, Gladstone Institute of Virology and Immunology, on finding a new potential pathway for HIV treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 498: December 20, 2013<\/h4>\n

\"498\"Magali Haas, M.D., Ph.D., M.S.E.,<\/strong> Founder and CEO of Orion Bionetworks, on using big data for disease modeling in multiple sclerosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 495: November 22, 2013<\/h4>\n

\"495\"Edwin Moses, Ph. D.,<\/strong> Chairman and CEO of Ablynx, on developing novel proteins based on single-domain antibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 494: November 15, 2013<\/h4>\n

\"494\"Laura Shawver, Ph.D.,<\/strong> CEO of Cleave Biosciences, on discovering and developing small molecules for targets in protein degradation pathways for cancer treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 491: October 25, 2013<\/h4>\n

\"491\"Sakhrat Khizroev, Ph.D.,<\/strong> Professor and Vice Chair, Department of Immunology, College of Medicine, and Director, Center for Personalized Nanomedicine, Florida International University, on opening new horizons in medicine with magneto-electric nanoparticles.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 489: October 11, 2013<\/h4>\n

\"489\"Dan Paterson,<\/strong> Chief Business Officer and Brian Sullivan,<\/strong> Corporate Development Director, Verastem, Inc., on selectively targeting cancer stem cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 486: September 20, 2013<\/h4>\n

\"486\"Nancy Simonian, M.D.,<\/strong> CEO of Syros Pharmaceuticals, on using super-enhancers to identify the genes driving disease and then developing drugs that inhibit or disrupt those targets.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 485: September 13, 2013<\/h4>\n

\"485\"Michel Sadelain, M.D., Ph.D.,<\/strong> Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center, on opening new horizons for cancer immunotherapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 483: August 30, 2013<\/h4>\n

\"483\"Derek A. Small,<\/strong> President and CEO and Joseph R. Moskal,<\/strong> Founder and Chief Scientific Officer of Nuarex Inc., on modulating the NMDA receptor for treatment of depression and other CSN disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 482: August 23, 2013<\/h4>\n

\"482\"<\/strong>Malcom Weir, Ph.D.,<\/strong> Co-founder and CEO of Heptares Therapeutics, on targeting G protein-coupled receptors for Alzheimer\u2019s Disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 481: August 9, 2013<\/h4>\n

\"481\"Masashi Yanagisawa, M.D., Ph.D.,<\/strong>
\nProfessor of University of Texas Southwestern Medical School and Tsukuba University, on developing orexin receptor agonist in the field of medicinal chemistry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 479: July 26, 2013<\/h4>\n

\"479\"Alain D. Baron, M.D., <\/strong>President and CEO, Elcelyx Therapeutics, on how their delayed release formulation of metformin, works.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 477: July 12, 2013<\/h4>\n

\"477\"Jae Chung, <\/strong>Founder and CEO, goBalto Inc., on goBalto\u2019s Tracker 2.0 cloud-based solution and the clinical study startup process.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 472: May 31, 2013<\/h4>\n

\"472\"Paul L. Hallenbeck, Ph.D., <\/strong>President and CEO, Synbody Biotechnology Inc., on the company\u2019s synbody platform and partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 470: May 17, 2013<\/h4>\n

\"470\"John Holland,<\/strong> Senior Vice President, Business Development and Research, AMC Health, on using remote monitoring in clinical trials and how the FDA is viewing such innovations in trial design.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 469: May 10, 2013<\/h4>\n

\"469\"Sapan Shah, Ph.D.<\/strong> President and Chief Executive Officer, ARMGO Pharma Inc., on the target mechanism in the company’s pipeline of novel compounds that utilize a defect in intracellular calcium regulation, and also on the company’s partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 467: April 26, 2013<\/h4>\n

\"467\"Pamela Tenaerts, MD, MBA,<\/strong> Executive Director, The Clinical Trials Transformation Initiative (CTTI), on the company’s activities in identifying practices that will increase the quality and efficiency of clinical trials.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 466: April 19, 2013<\/h4>\n

\"466\"Nathan Caffo<\/strong>, President, Presage Biosciences, on the company’s proprietary drug array platform for simultaneously analyzing multiple cancer drug candidates  within a single living tumor, and how pharmaceutical companies can use it to screen candidate compounds.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 464: April 5, 2013<\/h4>\n

\"464\"John A. Latham, Ph.D.,<\/strong> Chief Scientific Officer, and Mark J. Litton, Ph.D., MBA,<\/strong> Chief Business Officer and Treasurer, Alder Biopharmaceuticals, Inc, on the company’s development strategy for novel antibody therapeutics as a treatment for migraines.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 463: March 28, 2013<\/h4>\n

\"463\"Sanae Shoji, Ph.D,<\/strong> Former Research Associate at University of Texas Southwestern Medical Center, on her pioneering publication, \u201cIdentification of a candidate therapeutic autophagy-inducing peptide.\u201d<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 461: March 15, 2013<\/h4>\n

\"461\"James J. Collins, Ph.D., <\/strong>Co-founder, and Jeffrey D. Wager, M.D., <\/strong>Chairman, President and CEO, EnBiotix, Inc., on the company\u2019s technology and partnering strategy for its novel anti-bacterial platforms.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 459: March 1, 2013<\/h4>\n

\"459\"Destry Sulkes, M.D.,<\/strong> Executive Vice President and Co-founder, Medivo Inc,. on the company\u2019s services and how pharmaceutical companies can use them to deliver targeted communications to patients and doctors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 458: February 22, 2013<\/h4>\n

\"458\"Garret A. FitzGerald, M.D.,<\/strong> Chair, Department of Pharmacology, and Director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, on his group\u2019s research on molecular clocks in the regulation of biologic systems.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 457: February 15, 2013<\/h4>\n

\"shuhologo\"Jonathan Kil, M.D.,<\/strong> Chief Medical Officer and Director, Sound Pharmaceuticals, Inc., on SPI\u2019s development programs aiming to prevent and reverse hearing loss.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 455: February 1, 2013<\/h4>\n

\"shuhologo\"Thomas Kassberg<\/strong>, Chief Business Officer and Senior Vice President, Ultragenyx Pharmaceutical, on the company’s pipeline and strategy for developing treatments for rare and ultra-rare metabolic genetic disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 452: January 11, 2013<\/h4>\n

\"452\"Swati S. More, Ph.D,<\/strong> Research Associate, Center for Drug Design, University of Minnesota, on her findings from a study together with Professor Robert Vince, Ph.D., <\/strong> in which they found that a synthetic cofactor of glyoxalase was able to prevent neurodegeneration in a mouse model of Alzheimer’s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 450: December 21, 2012<\/h4>\n

\"450\"Ren\u00e9 Bernards, Ph.D.,<\/strong> Division Head, Molecular Carcinogenesis, The Netherlands Cancer Institute, on his research findings for a pathway that appears to confer resistance to a variety of cancer drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 448: December 7, 2012<\/h4>\n

\"shuhologo\"Christopher A. Kroeger, M.D.,<\/strong> President and CEO, Cardioxyl Pharmaceuticals, Inc, on the advantages of nitroxyl donors and the company\u2019s development programs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 446: November 16, 2012<\/h4>\n

\"446\"Michael Jirousek, Ph.D.,<\/strong> Co-founder and Chief Scientific Officer, Catabasis Pharmaceuticals, on the company’s lead program in  developing a pipeline focused on the treatment of inflammatory and metabolic diseases by employing its proprietary “linker” technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 445 November 9, 2012<\/h4>\n

\"445\"D. Lynn Kirkpatrick, Ph.D., <\/strong>President and CEO, Ensysce Biosciences Inc., on the company\u2019s technology and development programs for using single walled carbon nanotubes to deliver short interfering RNA (siRNA) for therapeutic applications in oncology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 443: October 26, 2012<\/h4>\n

\"443\"Elizabeth Iorns Ph.D.,<\/strong> Co-Founder & CEO, Science Exchange, on the concept behind and goals for the company’s Reproducibility Initiative, a program designed to help scientists validate studies for publication or commercialization.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 442: October 19, 2012<\/h4>\n

\"442\"Julian Bertschinger, Ph.D., <\/strong>Co-founder and Chief Executive Officer, Covagen AG, on the company’s technology platform for creatibng next-generation protein drugs, known as Fynomers, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 439: September 21, 2012<\/h4>\n

\"439\"Christopher Anzalone, Ph.D., <\/strong>President and CEO, Arrowhead Research Corporation, on the company\u2019s newly-acquired library of homing peptides and the company\u2019s development programs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 438: September 14, 2012<\/h4>\n

\"438\"Joseph F. Clark, Ph.D., <\/strong>Professor of Neurology, University of Cincinnati, on about his research findings in cyclocreatine as a treatment for creatine transporter deficiency, and the pathway ahead for clinical development of a treatment for the disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 436: August 31, 2012<\/h4>\n

\"436\"David Kaplan, Ph.D.,<\/strong> Stern Family Professor of Engineering, Professor and Chair, Department of Biomedical Engineering, Tufts University, on his research into the properties of silk and its biomedical applications.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 434: August 17, 2012<\/h4>\n

\"434\"Fumihiko Urano, M.D., Ph.D.,<\/strong> Associate Professor, School of Medicine, Washington University, on his research into how thioredoxin-interacting protein (TXIP) molecules are linked to both ER stress and the production of IL<\/em>-1\u03b2 <\/em>cytokine proteins within beta cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 431: July 27, 2012<\/h4>\n

\"431\"Werner Lanthaler, Ph.D.,<\/strong> Chief Executive Officer, Evotec AG, on the company\u2019s strengths in drug discovery and approach to partnering.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 430: July 20, 2012<\/h4>\n

\"430\"Michael Clayman, MD, <\/strong>Chief Executive Officer and Co-founder, Flexion Therapeutics,<\/em> on the company’s strategic focus, the status of its development programs, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 427: June 29, 2012<\/h4>\n

\"427\"Berislav V. Zlokovic, M.D., Ph.D.,<\/span><\/strong> Professor and Chair, Department of Physiology & Biophysics, and Director, Center for Neurodegeneration & Regeneration, Zilkha Neurogenetic Institute, Keck School of Medicine of USC on his research into the role of APOE4 in breakdowns in the blood-brain barrier.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 424: June 1, 2012<\/h4>\n

\"424\"Rangaramanujam M. Kannan, Ph.D., <\/strong>Professor of Ophthalmology, Center for Nanomedicine\/Wilmer Eye Institute, Johns Hopkins University School of Medicine, on results from his study on dendrimers for targeted treatment of neuroinflammation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 423: May 25, 2012<\/h4>\n

\"423\"Mark Bard,<\/strong> Co-Founder and Director, the Digital Health Coalition, on how pharmaceutical companies are using social media.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 422: May 18. 2012<\/h4>\n

\"422\"Nicholas P. Tatonetti, Ph.D. Candidate in Biomedical Informatics,<\/strong> Stanford University, on his research into an approach for controlling bias when performing data mining on an observational dataset of drug adverse events.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 421: May 11, 2012<\/h4>\n

\"421\"Anthony Goldbloom,<\/strong> Founder and CEO, Kaggle Inc., on the company\u2019s business model and how it helps companies and institutions find new ways of analyzing data.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 417: April 13, 2012<\/h4>\n

\"417\"Christian Zahnd, Ph.D.,<\/strong> CEO, and Patrick Amstutz, Ph.D.,<\/strong> Chief Business Officer, Molecular Partners AG, on the company\u2019s pipeline for developing a novel class of protein therapeutics called DARPins, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 416: April 5, 2012<\/h4>\n

\"416\"Guido Lanza,<\/strong> President and CEO, Numerate, Inc., on the company\u2019s approach to its in silico drug design, and its partnering model.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 415: March 30, 2012<\/h4>\n

\"415\"Professor Akira Sawa,<\/strong> Director, Silvio O. Conte Neuroscience Research Center, Johns Hopkins Schizophrenia Center, on the center\u2019s research into onset mechanisms for schizophrenia, focusing on both environmental and hereditary factors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 411: March 2, 2012<\/h4>\n

\"411\"Mason Tenaglia,<\/strong> Founder and Managing Director, The Amundsen Group, on the benefits of copay support programs for patients and manufacturers, and efforts to restrict the use of such programs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 410: February 24, 2012<\/h4>\n

\"410\"Paul M. Gilbert, <\/strong>Co-Founder and CEO, and Michael J. Detke, MD, PhD,<\/strong> Chief Medical Officer, MedAvante, Inc., on the company\u2019s approach to bringing greater standardization to patient assessments in CNS clinical trials through the use of centralized raters, and its activities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 409: February 17, 2012<\/h4>\n

\"409\"George G. Montgomery,<\/strong> Managing Director, Sagent Advisors, on M&A trends in the biopharma sector.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 401: December 16, 2011<\/h4>\n

\"401\"Hisataka Kobayashi, M.D., Ph.D.,<\/strong> National Cancer Institute, Molecular Imaging Program, on research into photoimmunotherapy, and its future outlook as a new treatment for cancer.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 400: December 9, 2011<\/h4>\n

\"400\"Bertrand C. Liang, M.D., Ph.D., M.B.A.,<\/strong> Chief Executive Officer, Pfenex Inc., on the company\u2019s unique protein expression platform that utilizes the microorganism Pseudomonas fluorescens<\/em> in a high-throughput process for rapidly identifying high-quality protein production strains, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 398: November 18, 2011<\/h4>\n

\"398\"Brian Overstreet,<\/strong> Co-founder and President, AdverseEvents, Inc., on the company\u2019s database of adverse drug events reported  the FDA, and its buisness model.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 397: November 11, 2011<\/h4>\n

\"397\"Marcus Wilson, Pharm.D.,<\/strong> President and Co-Founder of the HealthCore Unit of WellPoint, Inc., on the company\u2019s major collaboration with AstraZeneca, and its activities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 395: October 28, 2011<\/h4>\n

\"395\"Daniel Conners, <\/strong>Chairman and President, Biothera Pharmaceutical Group, on the company\u2019s development programs and partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 394: October 21, 2011<\/h4>\n

\"394\"P. Ron Ellis,<\/strong> Co-Founder, President, and CEO, Endocyte, Inc., on the company\u2019s technology platform for a pipeline of small molecule drug conjugates for treating cancer as well as inflammatory diseases, its development programs, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 393: October 14, 2011<\/h4>\n

\"393\"Richard A. Basile, <\/strong>CEO, BioPontis Alliance, LLC, on the company\u2019s model and plans.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 392: October 7, 2011<\/h4>\n

\"392\"David H. Kirn, M.D., <\/strong>Founder, President and CEO, Jennerex Biotherapeutics, Inc., on targeted oncolytic virus products for cancer, and the company\u2019s lead compound, JX-594.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 391: September 30, 2011<\/h4>\n

\"391\"Mark Pruzanski, M.D.,<\/strong> Founder, President and CEO, Intercept Pharmaceuticals, Inc., on the company\u2019s focus and partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 390: September 23, 2011<\/h4>\n

\"390\"Atul Butte, M.D., Ph.D., <\/strong>Division Chief and Associate Professor in Pediatrics (Systems Medicine), Medicine and Pediatrics, Stanford University School of Medicine, on his research into how expression data could be used to find new indications for existing drugs, and a new company he has founded for commercial applications of the technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 389: September 16, 2011<\/h4>\n

\"389\"Ramy Farid, Ph.D., <\/strong>President, and Shi-Yi Liu, Ph.D., <\/strong>Senior Vice President for Marketing, Schr\u00f6dinger, LLC, on the company\u2019s activities and its subsidiary in Japan.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 387: August 26, 2011<\/h4>\n

\"387\"Shinichi Takeda M.D., Ph.D.,<\/strong> Director, Translational Medical Center, National Center of Neurology and Psychology, on both the therapeutic potential of exon-skipping therapy for Duchenne muscular dystrophy and its continued doctoral research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 386: August 12, 2011<\/h4>\n

\"386\"Anthony McKinney, <\/strong>President, CEO and Co-Founder, Euthymics Bioscience, on the company\u2019s development programs for novel medicines for major depressive disorder and ADHD, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 385: August 5, 2011<\/h4>\n

\"shuhologo\"Gordon H. Busenbark,<\/strong> Senior Vice President and Chief Financial Officer, Inspiration Biopharmaceuticals, Inc. on the company\u2019s development programs for a pipeline of treatments for hemophilia, and the structure of its partnership with Ipse.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 383: July 22, 2011<\/h4>\n

\"383\"Anthony Costello, <\/strong>Chief Operating Officer, Mytrus, Inc. on the company\u2019s approach for enabling patients to participate in clinical trials from the convenience of their own homes, and the benefits for patients and pharmaceutical companies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 382: July 15, 2011<\/h4>\n

\"382\"Philip E. Bourne, Ph.D.,<\/strong> Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego on his findings and research approach to modeling the effects of a drug\u2019s interactions with multiple receptors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 381: July 8, 2011<\/h4>\n

\"381\"Chip Clark,<\/strong> President and Chief Executive Officer, Genocea Biosciences, on the company\u2019s vaccine technology platform, pipeline, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 380: July 1, 2011<\/h4>\n

\"380\"William J. Newell,<\/strong> CEO, Sutro Biopharma, Inc., on the company\u2019s biochemical protein synthesis technology platform and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 379: June 24, 2011<\/h4>\n

\"379\"Toru Hosoda, M.D., Ph.D., <\/strong>Associate Professor, Department of Medicine, National Institute of Science and Technology, Tokai University, on the first successful identification of stem cells from a human lung.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 378: June 17, 2011<\/h4>\n

\"378\"Katherine S. Bowdish, Ph.D.,<\/strong> Chief Executive Officer, Anaphore, Inc. on the company\u2019s Atrimer platform, in-house development initiatives, and its partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 376: June 3, 2011<\/h4>\n

\"376\"Shinichi Yachida, M.D., Ph.D., <\/strong>Research Associate, Department of Gastrointestinal Surgery, Kagawa University Hospital, on clarifying the genetic evolution and metastatic mechanisms of pancreatic cancer through genome analysis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 375: May 27, 2011<\/h4>\n

\"375\"Alan S. Klein<\/strong>, Executive Vice President, Corporate Development, Sequella Inc., on the company\u2019s new antibiotic mechanism for treating TB and helicobacter pylori.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 374: May 20, 2011<\/h4>\n

\"374\"Derek Chalmers, Ph.D.,<\/strong> President and CEO, Cara Therapeutics, Inc., on the company\u2019s development of a new analgesic without CNS Side Effects.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 370: April 21, 2011<\/h4>\n

\"370\"Scott Johnson, <\/strong>President and Founder, Myelin Repair Foundation, on how the company is pioneering a new model for drug discovery and developing a new approach to treating multiple sclerosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 369: April 15, 2011<\/h4>\n

\"369\"Dr. Krisztina Zsebo,<\/strong>
\nPresident and CEO, Celladon Corporation, on a genetically-targeted enzyme replacement therapy for treating heart failure.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Back to Recent Interviews<\/a><\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 367: April 1, 2011<\/h4>\n

\"367\"Scott Minick,<\/strong> President and CEO, BIND Biosciences, on the company’s therapeutic targeted nanoparticle technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 366: March 25, 2011<\/h4>\n

\"366\"Robert Shore, M.D., CEO,<\/strong> and Timothy Sullivan,<\/strong> Executive Vice President,
\nCornerstone Pharmaceuticals, on the company\u2019s drug delivery technology targeting cancer cell metabolism.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 364: March 11, 2011<\/h4>\n

\"364\"Robert L. Kirkman, M.D., <\/strong>President and CEO, and Scott Peterson, Ph.D.,<\/strong> Vice President of Research and Development, Oncothyreon, on the company\u2019s PI3K inhibitor.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 363: March 4, 2011<\/h4>\n

\"363\"Ernest Wong, Ph.D., M.B.A.,<\/strong> Vice President, YM Biosciences, about the company’s JAK inhibitor program in myelofibrosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 362: February 25, 2011<\/h4>\n

\"362\"Masayuki Yazawa, Ph.D.,<\/strong> Postdoctoral Research Fellow, Stanford University, on the use of iPS cells to treat Timothy Syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 361: February 18, 2011<\/h4>\n

\"361\"William S. Marshall, Ph.D.<\/strong> President and CEO of miRagen Therapeutics, about the company’s miRNA-targeted drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 358: January 28, 2011<\/h4>\n

\"361\"Arthur Sands, M.D., Ph.D.,<\/strong> President and CEO, Lexicon Pharmaceuticals, about the company’s development programs and partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 356: January 14, 2011<\/h4>\n

\"356\"Katrine Bosley,<\/strong> CEO of Avila Therapeutics, about the company’s discovery platform for targeted covalent drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 354: December 23, 2010<\/h4>\n

\"354\"Robert Kneller, J.D., M.D., M.P.H.,<\/strong> Professor, Research Center for Advanced Science and Technology (RCAST), University of Tokyo, on the differences between pharma and academia in drug discovery innovation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 353: December 17, 2010<\/h4>\n

\"353\"Aris Persidis, PhD.,<\/strong> President and Co-Founder, Biovista Inc., on using mechanism of action to predict safety and efficacy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 351: December 3, 2010<\/h4>\n

\"346\"Thomas Hughes, Ph.D.<\/strong>,<\/strong> President and CEO of Zafgen Inc., on the company’s lead candidate compound that promotes sustained weight loss through MetAP2 inhibition<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 350: November 19, 2010<\/h4>\n

\"350-1\"\"350-2\"\"350-3\"Eggehard Holler, Ph.D.<\/strong>, University of Regensburg, Julia Ljubimova, M.D., Ph.D.<\/strong>, Cedars-Sinai Medical Center, and Maurizio Vecchione<\/strong>, CEO, Arrogene Nanotechnology, on a nanoconjugate technology for treating brain …<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 348: November 5, 2010<\/h4>\n

\"348\"John E. Wennberg, M.D., M.P.H.,<\/strong> Peggy Y. Thomson Professor in the Evaluative Clinical Sciences, Dartmouth Medical School, on a rational approach to supply and demand in medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 346: October 22, 2010<\/h4>\n

\"346\"Tillman U. Gerngross, Ph.D.<\/strong>,<\/strong> CEO of Adimab Inc., on the company\u2019s novel antibody discovery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 343: October 1, 2010<\/h4>\n

\"343\"Kobi M. Sethna, <\/strong> President and CEO, Nereus Pharmaceuticals, on leveraging marine microbes as a source of novel pharmaceutical agents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 342: September 24, 2010<\/h4>\n

\"342\"Richard L. Atkinson, M.D., <\/strong>Clinical Professor of Pathology, Virginia Commonwealth University, and President, Obetech, LLC, on the evidence for a causal link between AD36 and obesity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 341: September 17, 2010<\/h4>\n

\"341\"Kathleen Sereda Glaub, <\/strong>President, Plexxikon, on the company’s lead drug candidate for melanoma.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 337: August 20, 2010<\/h4>\n

\"337\"Harald Fricke, M.D., Ph.D.,<\/strong> CMO and COO, Apogenix, on an innovative therapeutic approach to treating glioblastoma.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 336: August 6, 2010<\/h4>\n

\"336\"Stephen Engle,<\/strong> Chairman and CEO, XOMA, on developing a therapeutic antibody-based approach to diabetes treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 334: July 23, 2010<\/h4>\n

\"334\"Soichi Matsuno,<\/strong> Advisor, Eisai Co., Ltd., on how the company\u2019s pioneering spirit has contributed to its global expansion.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 333: July 15, 2010<\/h4>\n

\"333\"Maria L. Maccecchini, Ph.D.,<\/strong> President & CEO, QR Pharma, on an approach to inhibiting amyloid formation in targeting mild cognitive impairment and Alzheimer\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 332: July 7, 2010<\/h4>\n

\"332\"Marc Cantillon, M.D.,<\/strong> Director of the Coalition Against Major Diseases at the Critical Path Institute, on accelerating Alzheimer\u2019s drug development through data collaboration.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 328: June 4, 2010<\/h4>\n

\"328\"Gordon McCauley,<\/strong> President and CEO, Allon Therapeutics Inc., on targeting neurodegenerative diseases with activity-dependent neuroprotective protein.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 326: May 21, 2010<\/h4>\n

\"326\"\"326\"Robert Gould, Ph.D.,<\/strong> President and CEO, and Jason Rhodes,<\/strong> EVP and Chief Business Officer of Epizyme, on transforming cancer therapy via HMT inhibition.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 325: May 14, 2010<\/h4>\n

\"325\"Tom Smart,<\/strong> Chairman and CEO, AnaptysBio, on leveraging a novel platform for antibody generation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 322: April 23, 2010<\/h4>\n

\"322\"Roger H. Unger, M.D.,<\/strong> Professor of Internal Medicine, University of Texas South Western Medical Center, on the comparison of leptin and insulin levels in mouse models of type 1 diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 321: April 16, 2010<\/h4>\n

\"321\"Adam Bosworth,<\/strong> Founder and CTO of Keas, on using intelligent computing to improve patient outcomes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 316: March 12, 2010<\/h4>\n

\"316\"Christopher S. Meldrum,<\/strong> President, Pique Therapeutics, on non-immunogenic cancer treatment using allogenic vaccine therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 314: February 26, 2010<\/h4>\n

\"314\"Andrew M. Thompson<\/strong>, Co-Founder and CEO, Proteus Biomedical, on the company’s advancements in intelligent medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 312: February 12, 2010<\/h4>\n

\"312\"Stephen H. Friend, M.D., Ph.D.,<\/strong> President, CEO and Co-Founder, Sage Bionetworks, on the development of a shared data repository of clinical data to improve disease modeling.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 309: January 22, 2010<\/h4>\n

\"309\"Alpheus Bingham, Ph.D.,<\/strong> Founder and Director, InnoCentive Inc., on an incentive-based open innovation model for helping organizations solve research problems.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 305: December 18, 2009<\/h4>\n

\"305\"\"305\"Per Olof Wallstr\u00f6<\/strong>m, <\/strong>President and CEO, and Erika S\u00f6<\/strong>derberg Johnson, <\/strong>CFO, Karo Bio, on the development of innovative therapeutics targeting nuclear receptors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 304: December 11, 2009<\/h4>\n

\"304\"Joshua Kazam,<\/strong> President and CEO, Nile Therapeutics, on the company’s application of natriuretic peptides to treat heart failure.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 303: December 4, 2009<\/h4>\n

\"303\"Kees Been,<\/strong> President and CEO, EnVivo Pharmaceuticals, on enhancing cognitive function in Alzheimer’s disease and schizophrenia patients.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 302: November 20, 2009<\/h4>\n

\"302\"Benjamin Heywood, <\/strong>Co-Founder and President, PatientsLikeMe, on the company’s platform for connecting patients and pharma through social networking.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 301: November 13, 2009<\/h4>\n

\"301\"Randall L. Carpenter, M.D.,<\/strong> Co-Founder, President and CEO, Seaside Therapeutics, on the development of novel therapies for Fragile X Syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 300: November 6, 2009<\/h4>\n

\"300\"Joseph P. Pieroni,<\/strong> CEO, Daiichi Sankyo Inc., on the company’s marketing strategy for Effient.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 299: October 30, 2009<\/h4>\n

\"299\"Judy Mikovits,<\/strong> Ph.D<\/strong>, Director of Research at the Whittemore Peterson Institute, on the correlation between XMRV and Chronic Fatigue Syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 296: October 9, 2009<\/h4>\n

\"296\"David Rose,<\/strong> CEO, Vitality, on GlowCaps, the company’s breakthrough technology to promote medicine adherence.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 295: October 2, 2009<\/h4>\n

\"295\"Jennifer A. Low, MD, PhD, <\/strong>Global Clinical Lead for GTC-0449, Genentech, on Promising Early Clinical Results for a Hedgehog Inhibitor in Cancer.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 293: September 18, 2009<\/h4>\n

\"293\"Julia P. Gregory, <\/strong>President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 290: August 28, 2009<\/h4>\n

\"290\"Shingo Kajimura, Ph. D.<\/strong>,<\/strong> Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 289: August 21, 2009<\/h4>\n

\"289\"<\/strong>Robert H. Uhl, <\/strong> Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 288: August 14, 2009<\/h4>\n

\"288\"<\/strong>Dr. Gail Naughton,<\/strong> CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 286: July 31, 2009<\/h4>\n

\"286\"<\/strong>Neil Warma<\/strong>, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 283: July 10, 2009:<\/h4>\n

\"283\"<\/strong>Vijay B. Samant, <\/strong>President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 282: June 26, 2009<\/h4>\n

\"282\"<\/strong>Robert Gatenby, M.D., <\/strong>Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 281: June 19, 2009<\/h4>\n

\"281\"<\/strong>Vince Kuraitis, <\/strong>Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 280: June 12, 2009<\/h4>\n

\"280\"<\/strong>Gregory Perry, <\/strong>Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 278: May 29, 2009<\/h4>\n

\"278\"<\/strong>Saeid Akhtari, <\/strong>Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 277: May 22, 2009<\/h4>\n

\"277\"<\/strong>Shawn Lyndon, <\/strong>Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 276: May 15, 2009<\/h4>\n

\"276\"<\/strong>Eric Elliott, <\/strong>President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 275: May 8, 2009<\/h4>\n

\"275\"<\/strong>Edward Abrahams, Ph.D., <\/strong>Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 270: April 3, 2009<\/h4>\n

\"270\"<\/strong>Bruce S. Auerbach, M.D., FACEP, <\/strong>President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 269: March 27, 2009:<\/h4>\n

\"269\"<\/strong>Yoshimi Kuroiwa, Ph.D., <\/strong>Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 264: February 20, 2009<\/h4>\n

\"264\"<\/strong>Vincent Mutel, Ph.D., <\/strong>Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 263: February 13, 2009<\/h4>\n

\"263\"<\/strong>Jason Hwang, M.D., <\/strong>Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 260: January 13, 2009<\/h4>\n

\"260\"<\/strong>Scott Weir, PharmD, Ph.D., <\/strong>Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 259: January 16, 2009<\/h4>\n

\"259\"<\/strong>Mollie Shields-Uehling, <\/strong> President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 255: December 5, 2008<\/h4>\n

\"255\"<\/strong>Les Jordan, <\/strong> Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 254: Nobember 21, 2008<\/h4>\n

\"254\"<\/strong>Thomas Neyarapally, <\/strong> Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 252: Nobember 7, 2008<\/h4>\n

\"252\"<\/strong>Robert S. Becker, Ph.D., MBA, <\/strong> Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 251: October 31, 2008<\/h4>\n

\"251\"<\/strong>James J. O’Mara, <\/strong> Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 248: October 10, 2008<\/h4>\n

\"248\"<\/strong>Hironori Hozoji, <\/strong> Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 246: September 26, 2008<\/h4>\n

\"246\"<\/strong>David Steinberg<\/strong>, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 245: September 19, 2008<\/h4>\n

\"245\"<\/strong>Danong Chen, Ph.D.<\/strong>, President and CEO, Theranostics Health, on protein profiling and targeted therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 244: September 12, 2008<\/h4>\n

\"244\"<\/strong>Javier Gonzalez-Maeso, Ph.D.<\/strong>, Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 241: August 22, 2008:<\/h4>\n

\"241\"<\/strong>Ellen Coleman<\/strong>, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 240: August 8, 2008<\/h4>\n

\"240\"<\/strong>Nicholas J. Seay<\/strong>, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 239: August 1, 2008<\/h4>\n

\"239\"<\/strong>Jacqueline A. French, MD<\/strong>, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 233: June 13, 2008<\/h4>\n

\"233\"<\/strong>Howard Martin Fillit, M.D.<\/strong>, Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 231: May 30, 2008<\/h4>\n

\"231\"<\/strong>Jayakrishna Ambati, M.D.<\/strong>, Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 227: May 2, 2008<\/h4>\n

\"227\"<\/strong>Keizo Koya, Ph.D.<\/strong>, Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 225: April 18, 2008<\/h4>\n

\"225\"<\/strong>Anthony J. Varano, Jr.<\/strong>, Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 224: April 11, 2008:<\/h4>\n

\"224\"<\/strong>David G. Stevenson, S.M., Ph.D.<\/strong>, Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 223: April 4, 2008<\/h4>\n

\"223\"<\/strong>Joe Dougherty, Ph.D.<\/strong>, Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 221: March 20, 2008<\/h4>\n

\"221\"<\/strong>Adam J. Fein, Ph.D.<\/strong>, Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 217: February 22, 2008<\/h4>\n

\"217\"<\/strong>Bernhardt L. Trout<\/strong>, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 215: February 8, 2008<\/h4>\n

\"215\"<\/strong>Akiko Yabuuchi, Ph.D.<\/strong>, Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 213: January 25, 2008<\/h4>\n

\"213\"<\/strong>Joshua J. Spooner, PharmD, MS<\/strong>, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 293: September 18, 2009<\/h4>\n

\"293\"Julia P. Gregory, <\/strong>President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 290: August 28, 2009<\/h4>\n

\"290\"Shingo Kajimura, Ph. D.<\/strong>,<\/strong> Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 289: August 21, 2009<\/h4>\n

\"289\"<\/strong>Robert H. Uhl, <\/strong> Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 288: August 14, 2009<\/h4>\n

\"288\"<\/strong>Dr. Gail Naughton,<\/strong> CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 286: July 31, 2009<\/h4>\n

\"286\"<\/strong>Neil Warma<\/strong>, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 283: July 10, 2009:<\/h4>\n

\"283\"<\/strong>Vijay B. Samant, <\/strong>President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 282: June 26, 2009<\/h4>\n

\"282\"<\/strong>Robert Gatenby, M.D., <\/strong>Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 281: June 19, 2009<\/h4>\n

\"281\"<\/strong>Vince Kuraitis, <\/strong>Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 280: June 12, 2009<\/h4>\n

\"280\"<\/strong>Gregory Perry, <\/strong>Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 278: May 29, 2009<\/h4>\n

\"278\"<\/strong>Saeid Akhtari, <\/strong>Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 277: May 22, 2009<\/h4>\n

\"277\"<\/strong>Shawn Lyndon, <\/strong>Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 276: May 15, 2009<\/h4>\n

\"276\"<\/strong>Eric Elliott, <\/strong>President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 275: May 8, 2009<\/h4>\n

\"275\"<\/strong>Edward Abrahams, Ph.D., <\/strong>Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 270: April 3, 2009<\/h4>\n

\"270\"<\/strong>Bruce S. Auerbach, M.D., FACEP, <\/strong>President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 269: March 27, 2009:<\/h4>\n

\"269\"<\/strong>Yoshimi Kuroiwa, Ph.D., <\/strong>Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 264: February 20, 2009<\/h4>\n

\"264\"<\/strong>Vincent Mutel, Ph.D., <\/strong>Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 263: February 13, 2009<\/h4>\n

\"263\"<\/strong>Jason Hwang, M.D., <\/strong>Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 260: January 13, 2009<\/h4>\n

\"260\"<\/strong>Scott Weir, PharmD, Ph.D., <\/strong>Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 259: January 16, 2009<\/h4>\n

\"259\"<\/strong>Mollie Shields-Uehling, <\/strong> President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 255: December 5, 2008<\/h4>\n

\"255\"<\/strong>Les Jordan, <\/strong> Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 254: Nobember 21, 2008<\/h4>\n

\"254\"<\/strong>Thomas Neyarapally, <\/strong> Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 252: Nobember 7, 2008<\/h4>\n

\"252\"<\/strong>Robert S. Becker, Ph.D., MBA, <\/strong> Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 251: October 31, 2008<\/h4>\n

\"251\"<\/strong>James J. O’Mara, <\/strong> Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 248: October 10, 2008<\/h4>\n

\"248\"<\/strong>Hironori Hozoji, <\/strong> Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 246: September 26, 2008<\/h4>\n

\"246\"<\/strong>David Steinberg<\/strong>, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 245: September 19, 2008<\/h4>\n

\"245\"<\/strong>Danong Chen, Ph.D.<\/strong>, President and CEO, Theranostics Health, on protein profiling and targeted therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 244: September 12, 2008<\/h4>\n

\"244\"<\/strong>Javier Gonzalez-Maeso, Ph.D.<\/strong>, Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 241: August 22, 2008:<\/h4>\n

\"241\"<\/strong>Ellen Coleman<\/strong>, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 240: August 8, 2008<\/h4>\n

\"240\"<\/strong>Nicholas J. Seay<\/strong>, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 239: August 1, 2008<\/h4>\n

\"239\"<\/strong>Jacqueline A. French, MD<\/strong>, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 233: June 13, 2008<\/h4>\n

\"233\"<\/strong>Howard Martin Fillit, M.D.<\/strong>, Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 231: May 30, 2008<\/h4>\n

\"231\"<\/strong>Jayakrishna Ambati, M.D.<\/strong>, Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 227: May 2, 2008<\/h4>\n

\"227\"<\/strong>Keizo Koya, Ph.D.<\/strong>, Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 225: April 18, 2008<\/h4>\n

\"225\"<\/strong>Anthony J. Varano, Jr.<\/strong>, Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 224: April 11, 2008:<\/h4>\n

\"224\"<\/strong>David G. Stevenson, S.M., Ph.D.<\/strong>, Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 223: April 4, 2008<\/h4>\n

\"223\"<\/strong>Joe Dougherty, Ph.D.<\/strong>, Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 221: March 20, 2008<\/h4>\n

\"221\"<\/strong>Adam J. Fein, Ph.D.<\/strong>, Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 217: February 22, 2008<\/h4>\n

\"217\"<\/strong>Bernhardt L. Trout<\/strong>, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 215: February 8, 2008<\/h4>\n

\"215\"<\/strong>Akiko Yabuuchi, Ph.D.<\/strong>, Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 213: January 25, 2008<\/h4>\n

\"213\"<\/strong>Joshua J. Spooner, PharmD, MS<\/strong>, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 208: December 14, 2007<\/h4>\n

\"208\"<\/strong>Boro Dropulic, Ph.D., M.B.A<\/strong>, Founder and Chief Executive Officer, Lentigen, on the uses and advantages of his company’s Lentiviral Vector Platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 205: November 16, 2007<\/h4>\n

\"205\"<\/strong>Gerald Bernstein, M.D., F.A.C.P.<\/strong>, Vice President for Medical Affairs, Generex Biotechnology, on Generex’s Oral-lyn insulin product and the advantages of buccal delivery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 204: November 9, 2007<\/h4>\n

\"204\"<\/strong>Elizabeth Haanes, Ph.D.<\/strong>, Director, Sterne, Kessler, Goldstein & Fox P.L.L.C., on newly proposed Patent Office rules that would pose a hardship for the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 203: November 2, 2007<\/h4>\n

\"203\"<\/strong>Michael J. Krische, Ph.D.<\/strong>, Professor, Department of Chemistry and Biochemistry, University of Texas at Austin, on a byproduct-free method of creating carbon-carbon bonds through hydrogenation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 200: October 12, 2007<\/h4>\n

\"200\"<\/strong>William C. Crawford<\/strong> , Director of Industry Relations, Children’s Hospital Informatics Program, on creating a market for personally-controlled health records.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 199: October 5, 2007<\/h4>\n

\"148\"<\/strong>Gokhan S. Hotamisligil, M.D., Ph.D.<\/strong> , Chair, Department of Genetics and Complex Diseases, and J.S. Simmons Professor of Genetics & Metabolism, Harvard School of Public Health, on therapies at the interface of metabolic and inflammatory diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 198: September 28, 2007<\/h4>\n

\"198\"<\/strong>Daniel J. Carlat, M.D.<\/strong> , Assistant Clinical Professor of Psychiatry, Tufts University School of Medicine, and Editor-in-Chief, The Carlat Psychiatry Report, on industry sponsorship of continuing medical education.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 197: September 21, 2007<\/h4>\n

\"197\"<\/strong>Paul Burn, Ph.D.<\/strong> , Senior Vice President of Research & Development, Juvenile Diabetes Research Foundation (JDRF), on JDRF’s increased focus on translational and clinical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 196: September 14, 2007<\/h4>\n

\"196\"<\/strong>Sara Rosenbaum,<\/strong> Chair, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, on the SCHIP reauthorization bill.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 194: August 31, 2007<\/h4>\n

\"194\"<\/strong>Frank Burroughs<\/strong> , President, Abigail Alliance for Better Access to Developmental Drugs, on his organization’s push for ACCESS legislation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 192: August 10, 2007<\/h4>\n

\"\"<\/strong>Pieter Muntendam M.D.<\/strong> , President and CEO, and Robert N. McBurney, Ph.D.<\/strong>, Senior Vice President, Research & Development, and Chief Scientific Officer, BG Medicine, on creating biomarkers as decision tools for molecular medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 189: July 20, 2007<\/h4>\n

\"189\"<\/strong>J. Scott Tarrant<\/strong> , VP of Business Development, Xceleron Inc., on prioritizing compounds with human PK data through microdosing studies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 188: July 13, 2007<\/h4>\n

\"188\"<\/strong>Barry J. Schindler, <\/strong> Shareholder, Greenberg Traurig, LLP, on unresolved points of contention in the proposed patent reform bill.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 187: July 6, 2007<\/h4>\n

\"187\"<\/strong>Eileen Hilton, M.D.<\/strong> , President and CEO, Biomedical Research Alliance of New York (BRANY), on BRANY’s one-stop service for multi-center clinical trials.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 186: June 29, 2007<\/h4>\n

\"186\"<\/strong>Naomi Aronson, Ph.D.<\/strong> , Executive Director, Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC), on technology assessments and comparative effectiveness reviews.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 182: June 29, 2007<\/h4>\n

\"182\"<\/strong>Michael Milburn, Ph.D.<\/strong> , Chief Scientific Officer, Metabolon, Inc., on using metabolomics in biomarker discovery and compound profiling.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 179: May 11, 2007<\/h4>\n

\"179\"<\/strong>Stuart W. Peltz, Ph.D.<\/strong> , President and CEO, PTC Therapeutics, on his company’s approach of using small molecules to regulate protein synthesis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 178: May 4, 2007<\/h4>\n

\"178\"<\/strong>Bruce W. MacLennan,<\/strong> Partner, Herrick Feinstein LLP, on negotiating licensing deals with biotech companies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 176: April 20, 2007<\/h4>\n

\"176\"<\/strong>Daniel B. Ravicher<\/strong> , President and Executive Director, Public Patent Foundation, on challenging bad patents to serve the public interest.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 175: April 13, 2007<\/h4>\n

\"175\"<\/strong>Jacques E. Rossouw, M.D.<\/strong> , Chief of Women’s Health Initiative Branch, National Heart, Lung, and Blood Institute, NIH, on refining treatment recommendations for hormone therapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 174: March 30, 2007<\/h4>\n

\"174\"<\/strong>Wayne Koberstein<\/strong> , Consultant, on trends and developments among some of the key companies within the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 172: March 16, 2007<\/h4>\n

\"172\"<\/strong>William A. Sarraille<\/strong> , Partner, Sidley Austin LLP, on the potential impact of CMS’s proposed rules regarding Average Manufacturer Price (AMP) in Medicaid<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 171: March 9, 2007<\/h4>\n

\"171\"<\/strong>Mark Kessel<\/strong> , Co-Founder and Managing Director, Symphony Capital, on Symphony Capital’s partnership approach to financing the development of early clinical-stage compounds.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 169: February 23, 2007<\/h4>\n

\"169\"<\/strong>William L. Warren<\/strong> , Partner, Sutherland Asbill & Brennan LLP, on Representative Waxman’s proposed bill on follow-on biologics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 167: February 9, 2007<\/h4>\n

\"167\"<\/strong>Lynn E. Eccleston<\/strong> , Attorney, McGuire Woods LLP, on the ramifications of the Supreme Court’s decision on declaratory judgments in MedImmune v. Genentech.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 164 and 165: January 19 and 26, 2007<\/h4>\n

\"164\"<\/strong>Shin-Ichiro Imai, M.D., Ph.D.<\/strong> Assistant Professor, Molecular Biology and Pharmacology, Washington University School of Medicine, on research into Sir2 and longevity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 161: December 22, 2006<\/h4>\n

\"161\"<\/strong>Kenneth A. Getz, <\/strong> Senior Research Fellow, Tufts Center for the Study of Drug Development, on factors affecting speed and efficiency in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 160: December 15, 2006<\/h4>\n

\"160\"<\/strong>Louis A. Tartaglia, Ph.D., <\/strong> Senior Vice President and General Manager of Drug Repositioning and Selection, Gene Logic, on Gene Logic’s drug repositioning business.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 159: December 8, 2006<\/h4>\n

\"159\"<\/strong>Gary P. Pisano<\/strong>, Professor, Harvard Business School, on his new book on the biotechnology industry, Science Business<\/em>.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 156: November 10, 2006<\/h4>\n

\"156\"<\/strong>Richard P. Burgoon, Jr., <\/strong>CEO, Aeolus Pharmaceuticals, Inc., on catalytic antioxidants and Aeolus’ corporate strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 155: November 3, 2006<\/h4>\n

\"155\"<\/strong>Marc Fisher, MD<\/strong>, Professor of Neurology, University of Massachusetts Medical School, on new approaches for clinical development of stroke therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 153: October 20, 2006<\/h4>\n

\"153\"<\/strong>Eric Button<\/strong>, President and Managing Director, The BioMarker Group, on integrating biomarkers into drug development programs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 152: October 13, 2006<\/h4>\n

\"152\"<\/strong>Alan Goldhammer<\/strong>, Associate Vice President Regulatory Affairs, Pharmaceutical Research and Manufacturers of America, on PhRMA’s views of the Institute of Medicine’s recommendations to improve drug safety.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 151: October 6, 2006<\/h4>\n

\"151\"<\/strong>Arthur M. Krieg, <\/strong>M.D., Senior Vice President, Research and Development, and Chief Scientific Officer, Coley Pharmaceutical Group, on Coley’s development of CpG oligonucleotide immunotherapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 150: September 29, 2006<\/h4>\n

\"150\"<\/strong>Brian P. Murphy,<\/strong> Partner, Morgan, Lewis & Bockius LLP, on unresolved issues in Hatch-Waxman settlement agreements.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 149: September 22, 2006<\/h4>\n

\"149b\"<\/strong>Mihael H. Polymeropoulos,<\/strong> M.D., CEO, and Chip Clark<\/strong>, Chief Business Officer, Vanda Pharmaceuticals, on Vanda’s genomics-based approach to product differentiation in the market for CNS treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 148: September 15, 2006<\/h4>\n

\"148\"<\/strong>Gokhan S. Hotamisligil, <\/strong>M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, on chemical chaperones that suppress ER stress as potential treatments for diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 147: September 8, 2006<\/h4>\n

\"147\"<\/strong>Fumihiko Urano, <\/strong>M.D., Assistant Professor, University of Massachusetts Medical School, on the role of IRE1 in insulin biosynthesis in response to ER stress.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 145: August 25, 2006<\/h4>\n

\"145\"<\/strong>Bruce E. Schneider,<\/strong> Executive Vice President and Chief of Operations, Wyeth Research, on Wyeth\u2019s adoption of a \u201clearn and confirm\u201d approach to clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 144: August 11, 2006<\/h4>\n

\"144\"<\/strong>Duane Thurman,<\/strong> Director, Prescription Drug Program, Washington State Health Care Authority, on the state\u2019s preferred drug list and efforts to promote evidence-based, cost-effective prescribing behavior.<\/p>\n

\n
\n
\n

Issue 143: August 4, 2006<\/h4>\n

\"143\"<\/strong>Craig Atwood,<\/strong> Assistant Professor, Department of Medicine, University of Wisconsin, on the Reproductive-Cell Cycle Theory of Aging.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 141: July 21, 2006<\/h4>\n

\"141\"<\/strong>Hiromi Yoshikawa,<\/strong> Chairman and CEO, Otsuka America Pharmaceutical, Inc., on the expansion of Otsuka’s pharmaceutical business in the US.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 140: July 14, 2006:<\/h4>\n

\"140\"<\/strong>Daniel L. Weiner,<\/strong> Senior Vice President, Software Products, Pharsight Corporation, on Pharsight’s CRADA with the FDA and the infrastructure required for modeling and simulation in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 139: July 7, 2006<\/h4>\n

\"139\"<\/strong>Garo H. Armen,<\/strong> Chairman and CEO, Antigenics Inc., on Oncophage, an experimental cancer vaccine using heat shock proteins.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 138: June 30, 2006<\/h4>\n

\"138\"<\/strong>Donald A. Berry<\/strong>, Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, on the use of Bayesian statistical methods in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 136: June 16, 2006<\/h4>\n

\"136\"<\/strong>John E. McDonough,<\/strong> Executive Director, Health Care For All, on new legislation designed to reduce the number of people without health insurance in Massachusetts.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 135: June 9, 2006<\/h4>\n

\"135\"<\/strong>Robert J. Feeney, Jr.,<\/strong> President & CEO, MedVantx, on his company’s Sample Centers that dispense free generic drug samples.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 134: June 2, 2006<\/h4>\n

\"134\"<\/strong>Dr. Anthony Hayward,<\/strong> Director, Division of Clinical Research Resources, National Center for Research Resources, NIH, on a new Roadmap initiative to promote clinical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 133: May 26, 2006<\/h4>\n

\"133\"<\/strong>Dr. Steve E. Phurrough,<\/strong> Director, Coverage & Analysis Group, CMS, on National Coverage Determinations for Part B Drugs in Medicare.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 132: May 19 , 2006<\/h4>\n

\"132\"<\/strong>Dr. Randall S. Stafford, <\/strong>Assistant Professor of Medicine, Stanford Prevention Research Center, on new research in off-label prescribing patterns.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 131: May 12, 2006<\/h4>\n

\"131\"<\/strong>Dr. Bruce Silver,<\/strong> VP of Global Product Development Services in Oncology, PRA International, on issues in cancer drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 129: April 21, 2006<\/h4>\n

\"129\"<\/strong>Dr. John T. Santini, Jr.<\/strong>, President, MicroCHIPS, Inc., on implantable devices for drug delivery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 128: April 13, 2006<\/h4>\n

\"128\"<\/strong>Diana Conmy, <\/strong>Corporate Director of Market Insights at IMS Health, on key developments for the pharmaceutical industry in 2005.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 127: April 7, 2006<\/h4>\n

\"127\"<\/strong>Paul J. Hastings,<\/strong> President and Chief Executive Officer of Oncomed, Inc., on drugs to target cancer stem cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 126: March 31, 2006<\/h4>\n

\"126\"<\/strong>Dr. David Sinclair,<\/strong> Associate Professor of Pathology at Harvard Medical School, on the effects of SIR2 on the aging process.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 125: March 24, 2006<\/h4>\n

\"125\"<\/strong>Dr. Abner L. Notkins, <\/strong>Chief of Experimental Medicine for the National Institute of Dental and Craniofacial Research at the NIH, on the use of autoantibodies in predictive medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 124: March 17, 2006<\/h4>\n

\"124\"<\/strong>Michael Valentino,<\/strong> Chief Consultant, PBM Strategic Healthcare Group, VA, on the VA\ufffdfs national formulary.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 123: March 10, 2006<\/h4>\n

\"123\"<\/strong>J.D. Kleinke,<\/strong> Chairman & Executive Director, Omnimedix Institute, on obstacles to the development of a viable HIT system.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 121:February 24, 2006<\/h4>\n

\"121\"<\/strong>Dr. Barry Davis<\/strong>, Principal Investigator & Director, ALLHAT Clinical Trials Center, on using the landmark ALLHAT results to change prescribing behavior.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 120: February 17, 2006<\/h4>\n

\"120\"<\/strong>Dr. Gerald Reaven,<\/strong> Professor Emeritus (Active) of Medicine, Stanford University, on insulin resistance syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 117: January 27, 2006<\/h4>\n

\"117\"<\/strong>Dr. Stanley Ip,<\/strong> Project Leader, and Dr. Peter Bonis<\/strong>, Primary Technical Expert, Tufts-New England Medical Center Evidence-based Practice Center, on the comparative effectiveness of treatments for gastroesophageal reflux disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 116: January 20, 2006<\/h4>\n

\"116\"<\/strong>Dr. Timothy Anderson<\/strong>, Senior Pharmaceutical Analyst, Prudential Equity Group, LLC, on pharmaceutical patent expirations in 2006.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 115:January 13, 2006<\/h4>\n

\"115\"<\/strong>Dr. Kazuko Nishikura,<\/strong> Professor, Gene Expression and Regulation Program, The Wistar Institute, on her research into RNA editing and microRNA.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 113: December 22, 2005<\/h4>\n

\"113\"<\/strong>Dr. Alice M. Rivlin, <\/strong>Senior Fellow in Economic Studies, The Brookings Institution, on the fiscal sustainability of Medicare spending.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 112:December 16, 2005<\/h4>\n

\"112\"<\/strong>James M. Karis<\/strong>, President & CEO, Entelos, Inc., on the role of in silico modeling in drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 110: December 2, 2005<\/h4>\n

\"110\"<\/strong>Jerry Avorn<\/strong>, Professor of Medicine, Harvard Medical School, on academic detailing and physician prescribing behavior.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 109: November 18, 2005<\/h4>\n

\"109\"<\/strong>Kenneth I. Kaitin<\/strong>, Director, Tufts Center for the Study of Drug Development, on recent drug output trends.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 108: November 11, 2005<\/h4>\n

\"108\"<\/strong>Joan Alker<\/strong>, Senior Researcher, Georgetown Health Policy Institute, on Florida\u2019s proposed changes to the state Medicaid program.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 107: November 4, 2005<\/h4>\n

\"107\"<\/strong>Joshua Shinoff<\/strong>, Licensing Officer, Office of Technology Licensing, on technology transfer at UC Berkeley.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 105: October 21, 2005<\/h4>\n

\"105\"<\/strong>John A. Scarlett<\/strong>, President and CEO, Tercica, on the company\u2019s newly approved treatment for short stature.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 103: October 7, 2005<\/h4>\n

\"103\"<\/strong>Jean R. Slutsky<\/strong>, Director, Center for Outcomes and Evidence, on MMA provisions affecting the Agency for Healthcare Research and Quality.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 102: September 30, 2005<\/h4>\n

\"102\"<\/strong>Dara A. Corrigan<\/strong>, Partner, Arnold & Porter, on new MMA priorities for the Inspector General\u2019s Office at HHS.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 101: September 23, 2005<\/h4>\n

\"101\"<\/strong>Larry Gold<\/strong>, CEO & Chairman of the Board, SomaLogic, Inc., on the uses of aptamer technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 100: September 16, 2005<\/h4>\n

\"100\"<\/strong>Larry D. Sasich<\/strong>, Staff Pharmacist, Public Citizen, on drug safety issues at the FDA.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 99: September 9, 2005<\/h4>\n

\"99\"<\/strong>Mark Heesen,<\/strong>President, National Venture Capital Association, on venture capital financing trends in the biotech industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 98: September 2, 2005<\/h4>\n

\"98\"<\/strong>Dr. John A. Gans<\/strong>, EVP and CEO, American Pharmacists Association, on the role of pharmacists in improving drug safety.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 97: August 26, 2005<\/h4>\n

\"97\"<\/strong>David Largaespada,<\/strong>Associate Professor, University of Minnesota Cancer Center, on a new method of cancer-gene identification using the Sleeping Beauty transposon.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 96: August 12, 2005<\/h4>\n

\"96\"<\/strong>Makoto Nishimura, <\/strong>President and CEO of Astellas Pharma US, Inc. on Astellas\u2019s strategy in U.S. market.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 93: July 22, 2005<\/h4>\n

\"93\"<\/strong>Sharon Anglin Treat,<\/strong> Executive Director, National Legislative Association on Prescription Drug Prices, on state-level initiatives to reduce prescription drug prices..<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 92: July 15, 2005<\/h4>\n

\"92\"<\/strong>Dr. Moriya Tsuji, <\/strong>Associate Professor, Aaron Diamond AIDS Research Center, Rockefeller University, on the discovery of new antigens that bind to the CD1d receptor and activate NKT cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 91: July 8, 2005<\/h4>\n

\"91\"<\/strong>Larry McComber,<\/strong> VP Contract and Program Services, Novation LLC, on GPO contracting for prescription drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 90: July 1, 2005<\/h4>\n

\"90\"<\/strong>Robert K. Passikoff, <\/strong>Founder and President, Brand Keys, Inc., on DTC corporate and product brand promotion.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 89: June 24, 2005<\/h4>\n

\"89\"<\/strong>Jeffrey I.D. Lewis,<\/strong> Partner, Patterson Belknap Webb & Tyler LLP, on the impact of the Integra v. Merck decision on pharmaceutical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 88: June 17, 2005<\/h4>\n

\"88\"<\/strong>Shabbir Dahod, <\/strong>President and CEO, SupplyScape Corporation, on developing an electronic pedigree for the pharmaceutical supply chain.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 86: May 27, 2005<\/h4>\n

\"86\"<\/strong>Michael Rosen,<\/strong> Chairman and CEO, Immune Cell Therapy, Inc., on the life sciences hub in the Midwest.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 84: May 13, 2005<\/h4>\n

\"84\"<\/strong>Gary Zammit, <\/strong>President and CEO, Clinilabs, Inc., on progress in developing treatments for sleep disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 80: April 15, 2005<\/h4>\n

\"80\"<\/strong>Frank M. Rapoport,<\/strong> Partner, McKenna Long & Aldridge LLP, on the BioShield legislation and the development of a biodefense industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 78: April 1, 2005<\/h4>\n

\"78\"<\/strong>Steve Powell, <\/strong>Vice President of Worldwide Sales, Phase Forward, Incorporated, on the use of electronic data capture in clinical trials<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 77: March 25, 2005<\/h4>\n

\"77\"<\/strong>Christopher Watts,<\/strong> Staff Fellow, Center for Drug Evaluation and Research, FDA, on moving to real time release with PAT.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 76: March 18, 2005<\/h4>\n

\"76\"<\/strong>Daniel Devine,<\/strong> President and CEO, Acceptys, Inc., on shifting from humanized to fully-human monoclonal antibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 75: March 11, 2005<\/h4>\n

\"75\"Alton C. Morgan<\/strong>, Chairman and President, InNexus Biotechnology, Inc., on the development of SuperAntibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 73: February 25, 2005<\/h4>\n

\"73\"Paul Cusenza<\/strong>, Vice President, Alliance Management, Perlegen Sciences, Inc., on Perlegen\u2019s approach to high-density, whole genome SNP genotyping.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 72: February 18, 2005<\/h4>\n

\"72\"Derek Guyton<\/strong>, Principal, Mercer Human Resources Consulting, on how employer-sponsored retiree drug benefits are being affected by the MMA.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 69: January 28, 2005<\/h4>\n

\"69\"Steven H. Sklar<\/strong>, Partner, Leydig, Voit & Mayer, Ltd., on the Teva v. Pfizer decision on declaratory judgment actions.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 68: January 21, 2005<\/h4>\n

\"68\"Vera Hassner Sharav<\/strong>, President, Alliance for Human Research Protection, on how industry practices in clinical trials have led to an erosion of public trust.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 65: December 24, 2004<\/h4>\n

\"65\"Maxine Gowen<\/strong>, Managing Partner, SR One, on the investment approach of a venture capital subsidiary of a major pharmaceutical company.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 64: December 17, 2004<\/h4>\n

\"64\"Jennifer Covich Bordenick, MA,<\/strong> Director of Strategic Programs, eHealth Initiative, on the adoption of e-prescribing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 63: December 10, 2004<\/h4>\n

\"63\"John Santa<\/strong>, Medical Director of the Center for Evidence-based Policy at Oregon Health and Science University, on state initiatives to create a transparent drug evaluation system for more cost-effective drug spending.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 61: November 19, 2004<\/h4>\n

\"61\"J. David Haddox<\/strong>, Vice President, Risk Management & Health Policy, Purdue Pharma, on a government-aided, multifaceted approach to reduce the potential for abuse of prescription pain treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 59: November 5, 2004<\/h4>\n

\"59\"<\/strong>Mark Merritt<\/strong>, President and CEO, Pharmaceutical Care Management Association, on the role of pharmacy benefit managers in the Medicare prescription drug benefit.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 57: October 22, 2004<\/h4>\n

\"57\"<\/strong>Joseph S. McCracken<\/strong>, Vice President, Business Development, Genentech, Inc., on Genentech’s approach to R&D and commercialization partnerships.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 56: October 15, 2004<\/h4>\n

\"56\"Kathleen Jaeger, <\/strong>President and CEO, Generic Pharmaceutical Association, on the scientific advancements facilitating regulatory evaluations of biogenerics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 55: October 8, 2004<\/h4>\n

\"55\"<\/strong>Richard C. Aulatta<\/strong>, President, R.C. Auletta and Co., on Merck’s handling of the Vioxx recall.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 52: September 17, 2004<\/h4>\n

\"52\"Michael Krensavage<\/strong>, Senior Vice President, Equity Research, Raymond James & Associates, on Schering-Plough’s turnaround strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 51: September 10, 2004<\/h4>\n

\"51\"<\/strong>Richard D. Kelly<\/strong>, Senior Partner, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., on issues relating to authorized generics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 49: August 20, 2004<\/h4>\n

\"49\"Jeffrey Aronin<\/strong>, Founder, President and COO, Ovation Pharmaceuticals, on Ovation’s niche market business strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 48: August 13, 2004<\/h4>\n

\"48\"Nobuya Oka<\/strong>, Executive Vice President, Takeda Pharmaceuticals North America, on Takeda’s strategy in the U.S. market.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 47: August 6, 2004<\/h4>\n

\"47\"Reeta Roy<\/strong>, Vice President, Global Citizenship and Policy, Abbott Laboratories, on Abbott’s AIDS initiatives in developing countries.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 45: July 23, 2004<\/h4>\n

\"45\"Kevin Outterson<\/strong>, Associate Professor of Law, West Virginia University, on the impact of the Australia-U.S. Free Trade Agreement on the market for pharmaceuticals.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 44: July 16, 2004<\/h4>\n

\"44\"Vamsi K. Mootha<\/strong>, M.D., Assistant Professor, Harvard Medical School, on the team-science approach to biomedical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 43: July 9, 2004<\/h4>\n

\"43\"Michael M. Gottesman<\/strong>, M.D., Deputy Director for Intramural Research, NIH, on intramural research at the NIH.<\/em><\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 42: July 2, 2004<\/h4>\n

\"42\"<\/strong>Barry Greene<\/strong>, Chief Operating Officer, Alnylam Pharmaceuticals, on RNAi therapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 41: June 25, 2004<\/h4>\n

\"41\"<\/strong>Carl B. Feldbaum<\/strong>, President, Biotechnology Industry Organization (BIO), on the development of BIO and the biotech industry during his tenure.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 40: June 18, 2004<\/h4>\n

\"40\"<\/strong>Donald W. Moran<\/strong>, President, The Moran Company, on New York Attorney General Eliot Spitzer’s fraud suit against GlaxoSmithKline.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 37: May 28, 2004<\/h4>\n

\"37\"<\/strong>Frank F. Bilstein <\/strong>(Left), Partner, and Razmic S. Gregorian, Jr. <\/strong>(Right), Director, Simon-Kucher & Partners, on the impact of the Medicare legislation on the environment for drug pricing in the U.S.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 36: May 21, 2004<\/h4>\n

\"36\"Robert Monaghan <\/strong>(Left), CEO, and Lawrence K. Cohen <\/strong>(Right), Vice Chairman, Zyomyx Inc., on the use of protein chips in drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 35: May 14, 2004<\/h4>\n

\"35\"Viren Mehta<\/strong>, Managing Member, Mehta Partners LLC, on the merits of the Sanofi-Aventis merger .<\/em><\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 34: May 7, 2004<\/h4>\n

\"34\"John Rother<\/strong>, Director of Policy and Strategy, AARP, on the new Medicare drug discount cards and legislative reform priorities for Medicare.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 32: April 23, 2004<\/h4>\n

\"32\"Merrill Goozner<\/strong>, Journalist and Project Director, Center for Science in the Public Interest, on his new book, The $800 Million Pill.<\/em><\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 31: April 16, 2004<\/h4>\n

\"31\"Josef H. von Rickenbach<\/strong>, Chairman and CEO, PAREXEL International, on current trends in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 30: April 9, 2004<\/h4>\n

\"30\"Scott Gottlieb<\/strong>, M.D.,Director of Medical Policy Development, FDA, on Mark McClellan’s tenure at the FDA. .<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

ssue 29: April 2, 2004<\/h4>\n

\"29\"Wayne Koberstein<\/strong>, Contributing Editor, Contract Pharma, on globalization, consolidation, and pharmaceutical market strategies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 28: March 26, 2004<\/h4>\n

\"28\"Barbara Yanni<\/strong>, Chief Licensing Officer and Vice President, Merck & Co., Inc., on Merck\u2019s in-licensing activities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 27: March 19, 2004<\/h4>\n

\"27\"Steven Rauscher<\/strong>, President and CEO, Genome Therapeutics, on the market launch of Factive.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 26: March 12, 2004<\/h4>\n

\"26\"Richard Trabert<\/strong>, Public affairs consultant and faculty member at Boston College\u2019s Center for Corporate Citizenship, on social initiatives in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 25: March 5, 2004<\/h4>\n

\"25\"<\/strong>Lowell E. Schnipper<\/strong>, M.D., Harvard Medical School Professor and Chief of Hematology and Oncology at Beth Israel Deaconess Medical Center, on synergies between new and existing treatments in oncology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 24: February 27, 2004<\/h4>\n

\"24\"Soichi Matsuno<\/strong>, Chairman, Eisai Inc., on Eisai\u2019s strategy in the U.S. market.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 23: February 20, 2004<\/h4>\n

\"23\"<\/strong>Donald O. Beers<\/strong>, Partner, Arnold & Porter, on polymorph patents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 22: February 13, 2004<\/h4>\n

\"22\"Ken Araki<\/strong>, Pharmaceutical Industry Global Research Director, Nomura Securities International, on the forces shaping change in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 21: February 6, 2004<\/h4>\n

\"21\"Jean-Paul Modde<\/strong>, Group President, Dendrite International, Inc., on new trends in CRM in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 19: January 23, 2004<\/h4>\n

\"19\"Kevin Goodno<\/strong>, Commissioner, Minnesota Department of Human Services, on Minnesota\u2019s initiatives toward prescription drug importation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 18: January 16,2004<\/h4>\n

\"18\"Preston Henske<\/strong>, Vice President, Bain & Company, on building a new business model in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 15: December 12, 2003<\/h4>\n

\"15\"Kenneth S. Abramowitz<\/strong>, Senior Advisor, The Carlyle Group, on the impact of Medicare reforms on the HMO industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 14: December 5, 2003<\/h4>\n

\"14\"Anthony Robbins, M.D.<\/strong>, Professor of Public Health, Tufts University School of Medicine, on Medicare reform in historical perspective.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 12: November 21, 2003<\/h4>\n

\"12\"Louis M. Solomon<\/strong>, Partner, Proskauer Rose LLP, on Hatch-Waxman reforms.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 11: November 14, 2003<\/h4>\n

\"11\"Sharon Treat<\/strong>, Senate Majority Leader, State of Maine, on Maine\u2019s initiatives to lower the cost of prescription drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 10: November 7, 2003<\/h4>\n

\"10\"Nick Naclerio<\/strong>, President, ParAllele BioSciences, on pushing the boundaries of high-throughput SNP genotyping.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 9: October 31, 2003<\/h4>\n

\"9\"Vibeke Strand, M.D.<\/strong>, Adjunct Clinical Professor, Division of Immunology, Stanford University, on new treatment therapies for rheumatiod arthritis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 7: October 17, 2003<\/h4>\n

\"\"<\/strong>Christopher D.<\/strong> Hook<\/strong>, Director for RFID Market Development & Deborah H. Murphy, Life Sciences Market Development Manager, Zebra Technologies, on technologies for pharmaceutical supply chains.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 6: October 10, 2003<\/h4>\n

\"6\"Brian G. Atwood,<\/strong> Managing Director, Versant Ventures, on biotech venture capital investing and market cycles.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 5: October 3, 2003<\/h4>\n

\"5\"Glenn Rice<\/strong>, Vice President for Biopharmaceutical Sciences, SRI International, on bridging the gap from university research labs to clinical trials.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 4: September 26, 2003<\/h4>\n

\"\"Eric Lindsey<\/strong>, Vice President for Business Development, PDI Inc., on salesforce outsourcing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 3: September 19, 2003<\/h4>\n

\"\"Jack Trout<\/strong>, President, Trout & Partners, Ltd., on product positioning through DTC advertising.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 2: September 12, 2003<\/h4>\n

\"\"Tom Heyman<\/strong>, Executive Vice President for Business Development, Johnson & Johnson, on J&J\u2019s in-licensing activities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1: September 5, 2003<\/h4>\n

\"\"Paula Campbell Evans<\/strong>, Partner, Palmer & Dodge LLP, on the regulatory prospects for generic biologics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Archieve interview before 2025 Recent interviews Issue 1028: January 17, 2025 B. Frank Gupton, Ph.D., Chief Executive Officer, Medicines for All Institute at Virginia Commonwealth University, on eliminating waste and inefficiency in the drug manufacturing process. Issue 1025: December 20, 2024 Kelly Cobey, Ph.D., Scientist at the University of Ottawa Heart Institute, on the problems […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-562","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages\/562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/comments?post=562"}],"version-history":[{"count":11,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages\/562\/revisions"}],"predecessor-version":[{"id":777,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages\/562\/revisions\/777"}],"wp:attachment":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/media?parent=562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}